Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016

Abkürzungsverzeichnis

ACPO: akute colonische Pseudoobstruktion, syn. Ogilvie-Syndrom

CED: chronisch entzündliche Darmerkrankungen

CI: Confidence Interval, engl.

CIPO: chronische intestinale Pseudoobstruktion

CMV: Cytomegalie-Virus

ENS: enterisches Nervensystem

FBDSI: Functional Bowel Disorder Severity Index

FBS: Funktionelle Bauchschmerzen (engl. FAB, functional abdominal pain)

FD: Funktionelle Dyspepsie

GSRS-IBS: Gastrointestinal Symptom Rating Score

HADS: Hospital Anxiety Depression Scale, engl.

H&E: Hämatoxylin-Eosin-Färbung

IBS: Irritable Bowel Syndrome, engl.

IBS-IS: Irritable Bowel Syndrome Impact scale, engl.

IBS-SSS: IBS-severity scoring system, engl.

ICC: interstitielle Cajal-Zellen (engl. cells)

IMC: idiopathisches Megacolon/-rektum

LGG: Lactobacillus GG

NNT: Number Needed to Treat, engl.

NTC: Normal Transit Constipation, engl.

SERT: Serotoninwiederaufnahme (engl. reuptake)-Transporter

STC: Slow-Transit Constipation, engl.

QOL: Quality of Life, engl.

PBMC: periphere mononukleäre Blutzellen

PHQ: Patient Health Quenstionnaire

PI-RDS: Postinfektiöses Reizdarmsyndrom

RCT: radomisierte, kontrollierte Studie (engl. randomized controlled trial)

PTSD: Posttraumatic Stress Disorder, engl.

RDS: Reizdarmsyndrom

RDS-A: RDS mit wechselndem (alternierendem) Stuhlverhalten (z. B. Phasen von Diarrhoe im Wechsel mit Phasen von Obstipation)

RDS-D: Reizdarmsyndrom, diarrhoe-prädominant

RDS-O: Reizdarmsyndrom, obstipation-prädominant

RDS-M: Reizdarmsyndrom mit gemischtem Stuhlverhalten (z. B. innerhalb eines Tages sowohl Diarrhoe als auch Obstipation)

SSRI: Selektive Serotonin-Wiederaufnahmehemmer (engl. reuptake inhibitor)

TCA: Trizyklische Antidepressiva

Publikationsverlauf

Artikel online veröffentlicht:
10. Dezember 2021

• Literatur

• 1 Layer P, Andresen V, Pehl C. et al [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011; 49: 237-293
• 2 Phillips BDM, Ball C, Sackett D. et al Oxford Centre for Evidence-based Medicine – Levels of Evidence. In: CEBM 2009; 2009
• 3 Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 371-384
• 4 Manning AP, Thompson WG, Heaton KW. et al Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-654
• 5 Kruis W, Thieme C, Weinzierl M. et al A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7
• 6 Thompson WG, Dotevall G, Drossman DA. et al Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989; 2: 92-95
• 7 Thompson WG, Longstreth GF, Drossman DA. et al Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 02) II43-II47
• 8 Longstreth GF, Thompson WG, Chey WD. et al Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
• 9 Lacy BE, Mearin F, Chang L. et al Bowel Disorders. Gastroenterology 2016; 150: 1393-1407
• 10 Marshall JK, Thabane M, Borgaonkar MR. et al Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5: 457-460
• 11 Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut 1984; 25: 1089-1092
• 12 Talley NJ, Phillips SF, Melton LJ. et al Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990; 31: 77-81
• 13 Rao KP, Gupta S, Jain AK. et al Evaluation of Manning’s criteria in the diagnosis of irritable bowel syndrome. J Assoc Physicians India 1993; 41: 357-358, 363
• 14 Jeong H, Lee HR, Yoo BC. et al Manning criteria in irritable bowel syndrome: its diagnostic significance. Korean J Intern Med 1993; 8: 34-39
• 15 Zighelboim J, Talley NJ. What are functional bowel disorders?. Gastroenterology 1993; 104: 1196-1201
• 16 Hotz J, Enck P, Goebell H. et al [Consensus report: irritable bowel syndrome – definition, differential diagnosis, pathophysiology and therapeutic possibilities. Consensus of the German Society of Digestive and Metabolic Diseases]. Z Gastroenterol 1999; 37: 685-700
• 17 Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep 2017; 19: 15
• 18 Palsson OS, Whitehead WE, van Tilburg MAL. et al Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology 2016; 150: 1481-1491
• 19 Enck P, Frieling T, Schemann M. Irritable bowel syndrome – dissection of a disease. A 13-steps polemic. Z Gastroenterol 2017; 55: 679-684
• 20 Lacy BE, Lee RD. Irritable bowel syndrome: a syndrome in evolution. J Clin Gastroenterol 2005; 39: S230-242
• 21 Howship J. Practical remarks on the discrimination and successful treatment of spasmodic stricture in the colon considered as an occasional cause of habitual confinement of the bowel. London: 1830
• 22 Da Costa JM. Mucous enteritis. Am J Med Sci 1871; 62: 321-338
• 23 Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet 1997; 350: 1691-1695
• 24 Bockus HL, Bank J, Wilkinson SA. Neurogenic mucous colitis. Am J Med Sci 1928; 176: 813-829t
• 25 Ryle JA. Chronic spasmodic afflictions of the colon. Lancet II 1928; 212: 1115-1119
• 26 Smits BJ. The irritable bowel syndrome. Practitioner 1974; 213: 37-46
• 27 Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962; 31: 307-322
• 28 Frieling T, Schemann M, Pehl C. [Irritable bowel syndrom – a misnomer?]. Z Gastroenterol 2011; 49: 577-578
• 29 von Wulffen M, Talley NJ, Hammer J. et al Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2019; 64: 480-486
• 30 Spiller R, Aziz Q, Creed F. et al Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-1798
• 31 Drossman DA, McKee DC, Sandler RS. et al Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95: 701-708
• 32 Blewett A, Allison M, Calcraft B. et al Psychiatric disorder and outcome in irritable bowel syndrome. Psychosomatics 1996; 37: 155-160
• 33 Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?. Am J Med 1999; 107: 41S-50S
• 34 Smith RC, Greenbaum DS, Vancouver JB. et al Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome. Gastroenterology 1990; 98: 293-301
• 35 Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 2001; 96: 1340-1349
• 36 Locke 3rd GR, Weaver AL, Melton 3rd LJ. et al Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99: 350-357
• 37 Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304: 87-90
• 38 Heaton KW, Parker D, Cripps H. Bowel function and irritable bowel symptoms after hysterectomy and cholecystectomy – a population based study. Gut 1993; 34: 1108-1111
• 39 Mardini HE, Kip KE, Wilson JW. Crohn’s disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004; 49: 492-497
• 40 Kettell J, Jones R, Lydeard S. Reasons for consultation in irritable bowel syndrome: symptoms and patient characteristics. Br J Gen Pract 1992; 42: 459-461
• 41 Donker GA, Foets M, Spreeuwenberg P. Patients with irritable bowel syndrome: health status and use of health care services. Br J Gen Pract 1999; 49: 787-792
• 42 Icks A, Haastert B, Enck P. et al Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol 2002; 40: 177-183
• 43 Badia X, Mearin F, Balboa A. et al Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics 2002; 20: 749-758
• 44 Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721.e714
• 45 Ford AC, Forman D, Bailey AG. et al Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008; 103: 1229-1239 ; quiz 1240
• 46 Halder SL, Locke 3rd GR, Schleck CD. et al Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799-807
• 47 Brandt LJ, Chey WD, Foxx-Orenstein AE. et al An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl. 01) S1-S35
• 48 Hauser W, Marschall U, Layer P. et al The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome. Dtsch Arztebl Int 2019; 116: 463-470
• 49 Saito YA, Talley NJ, Melton LJ. et al The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil 2003; 15: 687-694
• 50 Andrews EB, Eaton SC, Hollis KA. et al Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005; 22: 935-942
• 51 Hungin AP, Chang L, Locke GR. et al Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-1375
• 52 Minocha A, Johnson WD, Abell TL. et al Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a population-based study. Dig Dis Sci 2006; 51: 446-453
• 53 Kumano H, Kaiya H, Yoshiuchi K. et al Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. Am J Gastroenterol 2004; 99: 370-376
• 54 Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402
• 55 Lackner JM, Jaccard J, Krasner SS. et al Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol 2008; 6: 899-906
• 56 Kanazawa M, Palsson OS, Thiwan SI. et al Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 2550-2561
• 57 Sabate JM, Veyrac M, Mion F. et al Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 484-490
• 58 Whitehead WE, Palsson OS, Levy RL. et al Reports of “satisfactory relief“ by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 1057-1065
• 59 Bray BD, Nicol F, Penman ID. et al Symptom interpretation and quality of life in patients with irritable bowel syndrome. Br J Gen Pract 2006; 56: 122-126
• 60 Drossman DA, Li Z, Toner BB. et al Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995; 40: 986-995
• 61 Sperber AD, Carmel S, Atzmon Y. et al Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000; 95: 995-998
• 62 Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-134
• 63 Wiklund IK, Fullerton S, Hawkey CJ. et al An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol 2003; 38: 947-954
• 64 Karling P, Danielsson A, Adolfsson R. et al No difference in symptoms of irritable bowel syndrome between healthy subjects and patients with recurrent depression in remission. Neurogastroenterol Motil 2007; 19: 896-904
• 65 Bengtsson M, Ohlsson B, Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol 2007; 7: 16
• 66 Posserud I, Syrous A, Lindstrom L. et al Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-1123
• 67 Spiegel B, Strickland A, Naliboff BD. et al Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536-2543
• 68 Hahn BA, Kirchdoerfer LJ, Fullerton S. et al Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553-559
• 69 Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005; 3: 717-725
• 70 Irvine EJ, Whitehead WE, Chey WD. et al Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-1551
• 71 Camilleri M, Mangel AW, Fehnel SE. et al Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007; 5: 534-540
• 72 Whitehead WE, Burnett CK, Cook EW. et al Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-2253
• 73 Brun-Strang C, Dapoigny M, Lafuma A. et al Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol 2007; 19: 1097-1103
• 74 Dean BB, Aguilar D, Barghout V. et al Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005; 11: S17-S26
• 75 Gralnek IM, Hays RD, Kilbourne A. et al The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-660
• 76 Frank L, Kleinman L, Rentz A. et al Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002; 24: 675-689 ; discussion 674
• 77 Halder SL, Locke 3rd GR, Talley NJ. et al Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 233-242
• 78 Creed F, Ratcliffe J, Fernandez L. et al Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 860-868
• 79 Hahn BA, Kirchdoerfer LJ, Fullerton S. et al Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 547-552
• 80 Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444-454
• 81 Patrick DL, Drossman DA, Frederick IO. et al Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-411
• 82 Chassany O, Marquis P, Scherrer B. et al Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 1999; 44: 527-533
• 83 Stewart AL, Hays RD, Ware JE. et al The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735
• 84 McHorney CA, Ware Jr JE, Lu JF. et al The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66
• 85 Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483
• 86 Lackner JM, Gudleski GD, Ma CX. et al Fear of GI symptoms has an important impact on quality of life in patients with moderate-to-severe IBS. Am J Gastroenterol 2014; 109: 1815-1823
• 87 Lackner JM, Gudleski GD, Thakur ER. et al The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am J Gastroenterol 2014; 109: 224-233
• 88 Jerndal P, Ringstrom G, Agerforz P. et al Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil 2010; 22: 646-e179
• 89 Michalsen VL, Vandvik PO, Farup PG. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Health Qual Life Outcomes 2015; 13: 113
• 90 Blagden S, Kingstone T, Soundy A. et al A Comparative Study of Quality of Life in Persons With Irritable Bowel Syndrome and Inflammatory Bowel Disease. Gastroenterol Nurs 2015; 38: 268-278
• 91 Liss JL, Alpers D, Woodruff RA. et al The irritable colon syndrome and psychiatric illness. Dis Nerv Syst 1973; 34: 151-157
• 92 Young SJ, Alpers DH, Norland CC. et al Psychiatric illness and the irritable bowel syndrome. Practical implications for the primary physician. Gastroenterology 1976; 70: 162-166
• 93 Lydiard RB, Fossey MD, Marsh W. et al Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993; 34: 229-234
• 94 Walker EA, Gelfand AN, Gelfand MD. et al Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995; 25: 1259-1267
• 95 Woodman CL, Breen K, Noyes Jr R. et al The relationship between irritable bowel syndrome and psychiatric illness. A family study. Psychosomatics 1998; 39: 45-54
• 96 Miller AR, North CS, Clouse RE. et al The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001; 13: 25-30
• 97 North CS, Downs D, Clouse RE. et al The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol 2004; 2: 787-795
• 98 North CS, Alpers DH, Thompson SJ. et al Gastrointestinal symptoms and psychiatric disorders in the general population. Findings from NIMH Epidemiologic Catchment Area Project. Dig Dis Sci 1996; 41: 633-640
• 99 Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001; 134: 868-881
• 100 Kanaan RA, Lepine JP, Wessely SC. The association or otherwise of the functional somatic syndromes. Psychosom Med 2007; 69: 855-859
• 101 Fossey MD, Lydiard RB. Anxiety and the gastrointestinal system. Psychiatr Med 1990; 8: 175-186
• 102 Walker EA, Roy-Byrne PP, Katon WJ. et al Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry 1990; 147: 1656-1661
• 103 Irwin C, Falsetti SA, Lydiard RB. et al Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry 1996; 57: 576-578
• 104 Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links?. J Clin Psychiatry 2001; 62 (Suppl. 08) 38-45 ; discussion 46-37
• 105 Walker EA, Katon WJ, Jemelka R. et al The prevalence of chronic pelvic pain and irritable bowel syndrome in two university clinics. J Psychosom Obstet Gynaecol 1991; 12: S65-75
• 106 Maunder RG. Panic disorder associated with gastrointestinal disease: review and hypotheses. J Psychosom Res 1998; 44: 91-105
• 107 Noyes Jr R, Cook B, Garvey M. et al Reduction of gastrointestinal symptoms following treatment for panic disorder. Psychosomatics 1990; 31: 75-79
• 108 Kaplan DS, Masand PS, Gupta S. The relationship of irritable bowel syndrome (IBS) and panic disorder. Ann Clin Psychiatry 1996; 8: 81-88
• 109 Lydiard RB. Increased prevalence of functional gastrointestinal disorders in panic disorder: clinical and theoretical implications. CNS Spectr 2005; 10: 899-908
• 110 Roy-Byrne PP, Davidson KW, Kessler RC. et al Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 2008; 30: 208-225
• 111 Gros DF, Antony MM, McCabe RE. et al Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disord 2009; 23: 290-296
• 112 Garakani A, Win T, Virk S. et al Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003; 10: 61-67
• 113 Cohen H, Jotkowitz A, Buskila D. et al Post-traumatic stress disorder and other co-morbidities in a sample population of patients with irritable bowel syndrome. Eur J Intern Med 2006; 17: 567-571
• 114 Liebschutz J, Saitz R, Brower V. et al PTSD in urban primary care: high prevalence and low physician recognition. J Gen Intern Med 2007; 22: 719-726
• 115 Savas LS, White DL, Wieman M. et al Irritable bowel syndrome and dyspepsia among women veterans: prevalence and association with psychological distress. Aliment Pharmacol Ther 2009; 29: 115-125
• 116 Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2001; 62 (Suppl. 08) 28-36 ; discussion 37
• 117 Perkins SJ, Keville S, Schmidt U. et al Eating disorders and irritable bowel syndrome: is there a link?. J Psychosom Res 2005; 59: 57-64
• 118 Boyd C, Abraham S, Kellow J. Psychological features are important predictors of functional gastrointestinal disorders in patients with eating disorders. Scand J Gastroenterol 2005; 40: 929-935
• 119 Nellesen D, Chawla A, Oh DL. et al Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med 2013; 125: 40-50
• 120 Enck P, Aziz Q, Barbara G. et al Irritable bowel syndrome. Nat Rev Dis Primers 2016; 2: 16014
• 121 Camilleri M, Halawi H, Oduyebo I. Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?. Expert Rev Gastroenterol Hepatol 2017; 11: 303-316
• 122 Scheemann M. Reizdarm und Reizmagen – Pathophysiologie und Biomarker. Der Gastroenterologe 2017; 12: 114-129
• 123 Camilleri M, Shin A, Busciglio I. et al Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 1677-1685
• 124 Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology 2016; 150: 1257-1261
• 125 Gunnarsson J, Simren M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-793
• 126 Camilleri M, McKinzie S, Busciglio I. et al Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-781
• 127 Manabe N, Wong BS, Camilleri M. et al Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 22: 293-e282
• 128 Ng C, Danta M, Kellow J. et al Attenuation of the colorectal tonic reflex in female patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2005; 289: G489-G494
• 129 Fukudo S, Kanazawa M, Kano M. et al Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 2002; 37 (Suppl. 14) 145-150
• 130 van der Veek PP, Steenvoorden M, Steens J. et al Recto-colonic reflex is impaired in patients with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 653-659
• 131 Lembo T, Munakata J, Naliboff B. et al Sigmoid afferent mechanisms in patients with irritable bowel syndrome. Dig Dis Sci 1997; 42: 1112-1120
• 132 Serra J, Villoria A, Azpiroz F. et al Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 401-406, e491–e402
• 133 Peleman C, Camilleri M, Busciglio I. et al Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption. Clin Gastroenterol Hepatol 2017; 15: 720-727 e721
• 134 Vijayvargiya P, Busciglio I, Burton D. et al Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples. Clin Gastroenterol Hepatol 2018; 16: 522-527
• 135 Piche T, Barbara G, Aubert P. et al Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201
• 136 Martinez C, Gonzalez-Castro A, Vicario M. et al Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver 2012; 6: 305-315
• 137 Gonzalez-Castro AM, Martinez C, Salvo-Romero E. et al Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. J Gastroenterol Hepatol 2017; 32: 53-63
• 138 Coeffier M, Gloro R, Boukhettala N. et al Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105: 1181-1188
• 139 Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-46
• 140 Larsson MH, Simren M, Thomas EA. et al Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 812-820
• 141 Medland JE, Pohl CS, Edwards LL. et al Early life adversity in piglets induces long-term upregulation of the enteric cholinergic nervous system and heightened, sex-specific secretomotor neuron responses. Neurogastroenterol Motil 2016; 28: 1317-1329
• 142 Blackshaw LA, Brookes SJ, Grundy D. et al Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007; 19: 1-19
• 143 Mertz H, Naliboff B, Munakata J. et al Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52
• 144 Ng C, Malcolm A, Hansen R. et al Distension technique influences the relationship between colonic and rectal hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 206-210
• 145 Scanzi J, Accarie A, Muller E. et al Colonic overexpression of the T-type calcium channel Cav 3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol Motil 2016; 28: 1632-1640
• 146 Munakata J, Naliboff B, Harraf F. et al Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 55-63
• 147 Serra J, Azpiroz F, Malagelada JR. Perception and reflex responses to intestinal distention in humans are modified by simultaneous or previous stimulation. Gastroenterology 1995; 109: 1742-1749
• 148 Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil 2009; 21: 23-32
• 149 Akbar A, Yiangou Y, Facer P. et al Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923-929
• 150 van Wanrooij SJ, Wouters MM, Van Oudenhove L. et al Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity?. Am J Gastroenterol 2014; 109: 99-109
• 151 Cenac N, Andrews CN, Holzhausen M. et al Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-647
• 152 Hughes PA, Harrington AM, Castro J. et al Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 2013; 62: 1456-1465
• 153 Spiller RC, Jenkins D, Thornley JP. et al Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811
• 154 Spiller R, Lam C. An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil 2012; 18: 258-268
• 155 Gupta S. Infectious disease: Something in the water. Nature 2016; 533: S114-S115
• 156 Collins SM, Chang C, Mearin F. Postinfectious Chronic Gut Dysfunction: From Bench to Bedside. The American Journal of Gastroenterology Supplements 2012; 1: 2-8
• 157 Schemann M, Camilleri M. Functions and imaging of mast cell and neural axis of the gut. Gastroenterology 2013; 144: 698-704 e694
• 158 Pike BL, Paden KA, Alcala AN. et al Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome. J Travel Med 2015; 22: 242-250
• 159 Liebregts T, Adam B, Bredack C. et al Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920
• 160 Bashashati M, Moossavi S, Cremon C. et al Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30
• 161 Wood JD, Liu S, Drossman DA. et al Anti-enteric neuronal antibodies and the irritable bowel syndrome. J Neurogastroenterol Motil 2012; 18: 78-85
• 162 Cremon C, Gargano L, Morselli-Labate AM. et al Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400
• 163 Barbara G, Stanghellini V, De Giorgio R. et al Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702
• 164 Klooker TK, Braak B, Koopman KE. et al The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-1221
• 165 Langhorst J, Junge A, Rueffer A. et al Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-410
• 166 Palsson OS, Morteau O, Bozymski EM. et al Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004; 49: 1236-1243
• 167 Dothel G, Barbaro MR, Boudin H. et al Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2015; 148: 1002-1011 e1004
• 168 Xu XJ, Zhang YL, Liu L. et al Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. Aliment Pharmacol Ther 2017; 45: 100-114
• 169 Berdun S, Rychter J, Vergara P. Effects of nerve growth factor antagonist K252a on peritoneal mast cell degranulation: implications for rat postoperative ileus. Am J Physiol Gastrointest Liver Physiol 2015; 309: G801-G806
• 170 Guarino MP, Barbara G, Cicenia A. et al Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. Neurogastroenterol Motil 2017; 29
• 171 Tornblom H, Lindberg G, Nyberg B. et al Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-1979
• 172 Buhner S, Li Q, Vignali S. et al Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-1434
• 173 Barbara G, Wang B, Stanghellini V. et al Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37
• 174 Buhner S, Li Q, Berger T. et al Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil 2012; 24: 1134-e1572
• 175 Buhner S, Braak B, Li Q. et al Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity. Exp Physiol 2014; 99: 1299-1311
• 176 Ostertag D, Buhner S, Michel K. et al Reduced Responses of Submucous Neurons from Irritable Bowel Syndrome Patients to a Cocktail Containing Histamine, Serotonin, TNFalpha, and Tryptase (IBS-Cocktail). Front Neurosci 2015; 9: 465
• 177 Wouters MM, Balemans D, Van Wanrooy S. et al Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology 2016; 150: 875-887 e879
• 178 El-Salhy M, Gilja OH. Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome. BMC Gastroenterol 2017; 17: 90
• 179 El-Salhy M, Hatlebakk JG, Gilja OH. et al Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides 2015; 67: 12-19
• 180 El-Salhy M. Recent advances in the diagnosis of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2015; 9: 1161-1174
• 181 El-Salhy M, Gundersen D, Ostgaard H. et al Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci 2012; 57: 873-878
• 182 Spiller R. Serotonin and GI clinical disorders. Neuropharmacology 2008; 55: 1072-1080
• 183 Grover M, Camilleri M, Smith K. et al On the fiftieth anniversary. Postinfectious irritable bowel syndrome: mechanisms related to pathogens. Neurogastroenterol Motil 2014; 26: 156-167
• 184 Mazzawi T, El-Salhy M. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Exp Biol Med (Maywood) 2017; 242: 1355-1362
• 185 Yano JM, Yu K, Donaldson GP. et al Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161: 264-276
• 186 Gazouli M, Wouters MM, Kapur-Pojskic L. et al Lessons learned – resolving the enigma of genetic factors in IBS. Nat Rev Gastroenterol Hepatol 2016; 13: 77-87
• 187 Kumar S, Ranjan P, Mittal B. et al Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis 2012; 21: 31-38
• 188 Cremon C, Carini G, Wang B. et al Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011; 106: 1290-1298
• 189 Stasi C, Bellini M, Gambaccini D. et al Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. J Neurogastroenterol Motil 2017; 23: 428-434
• 190 Atkinson W, Lockhart S, Whorwell PJ. et al Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43
• 191 Coates MD, Mahoney CR, Linden DR. et al Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664
• 192 Keszthelyi D, Troost FJ, Jonkers DM. et al Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state. J Psychosom Res 2013; 74: 501-504
• 193 Keszthelyi D, Troost FJ, Jonkers DM. et al Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome. Aliment Pharmacol Ther 2014; 40: 392-402
• 194 Keszthelyi D, Troost FJ, Jonkers DM. et al Visceral hypersensitivity in irritable bowel syndrome: evidence for involvement of serotonin metabolism--a preliminary study. Neurogastroenterol Motil 2015; 27: 1127-1137
• 195 Thijssen AY, Mujagic Z, Jonkers DM. et al Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther 2016; 43: 272-282
• 196 Mueller K, Michel K, Krueger D. et al Activity of protease-activated receptors in the human submucous plexus. Gastroenterology 2011; 141: 2088-2097 e2081
• 197 Gecse K, Roka R, Ferrier L. et al Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-599
• 198 Annahazi A, Gecse K, Dabek M. et al Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 2009; 144: 209-217
• 199 Kerckhoffs AP, Ter Linde JJ, Akkermans LM. et al Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008; 20: 900-907
• 200 Rolland-Fourcade C, Denadai-Souza A, Cirillo C. et al Epithelial expression and function of trypsin-3 in irritable bowel syndrome. Gut 2017; 66: 1767-1778
• 201 Buhner S, Hahne H, Hartwig K. et al Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients. PLoS One 2018; 13: e0193943
• 202 Desormeaux C, Bautzova T, Garcia-Caraballo S. et al Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons. Pain 2018; 159: 1257-1267
• 203 Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids – a diagnostic biomarker for irritable bowel syndrome?. BMC Gastroenterol 2016; 16: 51
• 204 Mayer EA, Gupta A, Kilpatrick LA. et al Imaging brain mechanisms in chronic visceral pain. Pain 2015; 156 (Suppl. 01) S50-S63
• 205 Mertz H, Morgan V, Tanner G. et al Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118: 842-848
• 206 Lawal A, Kern M, Sidhu H. et al Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006; 130: 26-33
• 207 Naliboff BD, Berman S, Chang L. et al Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003; 124: 1738-1747
• 208 Tanaka T, Manabe N, Hata J. et al Characterization of autonomic dysfunction in patients with irritable bowel syndrome using fingertip blood flow. Neurogastroenterol Motil 2008; 20: 498-504
• 209 Spaziani R, Bayati A, Redmond K. et al Vagal dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol Motil 2008; 20: 336-342
• 210 Spetalen S, Sandvik L, Blomhoff S. et al Autonomic function at rest and in response to emotional and rectal stimuli in women with irritable bowel syndrome. Dig Dis Sci 2008; 53: 1652-1659
• 211 Mazur M, Furgala A, Jablonski K. et al Dysfunction of the autonomic nervous system activity is responsible for gastric myoelectric disturbances in the irritable bowel syndrome patients. J Physiol Pharmacol 2007; 58 (Suppl. 03) 131-139
• 212 Liu Q, Wang EM, Yan XJ. et al Autonomic functioning in irritable bowel syndrome measured by heart rate variability: a meta-analysis. J Dig Dis 2013; 14: 638-646
• 213 Salvioli B, Pellegatta G, Malacarne M. et al Autonomic nervous system dysregulation in irritable bowel syndrome. Neurogastroenterol Motil 2015; 27: 423-430
• 214 Heitkemper M, Jarrett M, Cain K. et al Increased urine catecholamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol 1996; 91: 906-913
• 215 Heitkemper M, Jarrett M, Cain KC. et al Autonomic nervous system function in women with irritable bowel syndrome. Dig Dis Sci 2001; 46: 1276-1284
• 216 Mazurak N, Seredyuk N, Sauer H. et al Heart rate variability in the irritable bowel syndrome: a review of the literature. Neurogastroenterol Motil 2012; 24: 206-216
• 217 Polster A, Friberg P, Gunterberg V. et al Heart rate variability characteristics of patients with irritable bowel syndrome and associations with symptoms. Neurogastroenterol Motil 2018; 30: e13320
• 218 Tanaka Y, Kanazawa M, Palsson OS. et al Increased Postprandial Colonic Motility and Autonomic Nervous System Activity in Patients With Irritable Bowel Syndrome: A Prospective Study. J Neurogastroenterol Motil 2018; 24: 87-95
• 219 Mulak A, Tache Y, Larauche M. Sex hormones in the modulation of irritable bowel syndrome. World J Gastroenterol 2014; 20: 2433-2448
• 220 Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 2014; 20: 6725-6743
• 221 Kiank C, Tache Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 2010; 24: 41-48
• 222 Chatoo M, Li Y, Ma Z. et al Involvement of Corticotropin-Releasing Factor and Receptors in Immune Cells in Irritable Bowel Syndrome. Front Endocrinol (Lausanne) 2018; 9: 21
• 223 Markert C, Suarez-Hitz K, Ehlert U. et al Endocrine dysregulation in women with irritable bowel syndrome according to Rome II criteria. J Behav Med 2016; 39: 519-526
• 224 Suarez-Hitz KA, Otto B, Bidlingmaier M. et al Altered psychobiological responsiveness in women with irritable bowel syndrome. Psychosom Med 2012; 74: 221-231
• 225 Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am 2011; 40: 45-67
• 226 Lyons JJ, Yu X, Hughes JD. et al Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016; 48: 1564-1569
• 227 Wohlfarth C, Schmitteckert S, Hartle JD. et al miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Sci Rep 2017; 7: 14680
• 228 Henstrom M, Hadizadeh F, Beyder A. et al TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M. Gut 2017; 66: 1725-1727
• 229 Henstrom M, Diekmann L, Bonfiglio F. et al Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut 2018; 67: 263-270
• 230 Holliday EG, Attia J, Hancock S. et al Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Am J Gastroenterol 2014; 109: 770-772
• 231 Ek WE, Reznichenko A, Ripke S. et al Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut 2015; 64: 1774-1782
• 232 Bonfiglio F, Henstrom M, Nag A. et al A GWAS meta-analysis from 5 population-based cohorts implicates ion channel genes in the pathogenesis of irritable bowel syndrome. Neurogastroenterol Motil 2018; 30: e13358
• 233 Bonfiglio F, Zheng T, Garcia-Etxebarria K. et al Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology 2018; 155: 168-179
• 234 Dinan TG, Cryan J, Shanahan F. et al IBS: An epigenetic perspective. Nat Rev Gastroenterol Hepatol 2010; 7: 465-471
• 235 Mahurkar S, Polytarchou C, Iliopoulos D. et al Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. Neurogastroenterol Motil 2016; 28: 410-422
• 236 Liao XJ, Mao WM, Wang Q. et al MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome. Biochem Biophys Res Commun 2016; 469: 288-293
• 237 Codling C, O’Mahony L, Shanahan F. et al A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55: 392-397
• 238 Kassinen A, Krogius-Kurikka L, Makivuokko H. et al The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
• 239 Krogius-Kurikka L, Lyra A, Malinen E. et al Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95
• 240 Lyra A, Rinttila T, Nikkila J. et al Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009; 15: 5936-5945
• 241 Tana C, Umesaki Y, Imaoka A. et al Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512-519, e114-515
• 242 Kerckhoffs AP, Samsom M, van der Rest ME. et al Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887-2892
• 243 Jeffery IB, O’Toole PW, Ohman L. et al An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006
• 244 Chassard C, Dapoigny M, Scott KP. et al Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-838
• 245 Jalanka-Tuovinen J, Salojarvi J, Salonen A. et al Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737-1745
• 246 Jalanka J, Salonen A, Fuentes S. et al Microbial signatures in post-infectious irritable bowel syndrome – toward patient stratification for improved diagnostics and treatment. Gut Microbes 2015; 6: 364-369
• 247 Maharshak N, Ringel Y, Katibian D. et al Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Dig Dis Sci 2018; 63: 1890-1899
• 248 Villarreal AA, Aberger FJ, Benrud R. et al Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17-20
• 249 Tap J, Derrien M, Tornblom H. et al Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology 2017; 152: 111-123 e118
• 250 Bennet SMP, Bohn L, Storsrud S. et al Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut 2018; 67: 872-881
• 251 Gwee KA, Graham JC, McKendrick MW. et al Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-153
• 252 Ruigomez A, Wallander MA, Johansson S. et al One-year follow-up of newly diagnosed irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1097-1102
• 253 Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 410-413
• 254 Whitehead WE, Holtkotter B, Enck P. et al Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-1192
• 255 Naliboff BD, Munakata J, Fullerton S. et al Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997; 41: 505-512
• 256 Dorn SD, Palsson OS, Thiwan SI. et al Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-1209
• 257 Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis?. Am J Gastroenterol 1997; 92: 954-959
• 258 Elsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011; 25: 386-394
• 259 Keszthelyi D, Troost FJ, Masclee AA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: G141-G154
• 260 Boeckxstaens G, Camilleri M, Sifrim D. et al Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation. Gastroenterology 2016; S0016-5085(16)00221-3.
• 261 Mikocka-Walus A, Turnbull D, Moulding N. et al Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. J Gastroenterol Hepatol 2008; 23: 1137-1143
• 262 Elsenbruch S, Rosenberger C, Enck P. et al Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010; 59: 489-495
• 263 Grinsvall C, Tornblom H, Tack J. et al Psychological factors selectively upregulate rectal pain perception in hypersensitive patients with irritable bowel syndrome. Neurogastroenterol Motil 2015; 27: 1772-1782
• 264 Simren M, Tornblom H, Palsson OS. et al Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut 2018; 67: 255-262
• 265 Tanaka Y, Kanazawa M, Fukudo S. et al Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 131-139
• 266 Van Oudenhove L, Crowell MD, Drossman DA. et al Biopsychosocial Aspects of Functional Gastrointestinal Disorders. Gastroenterology 2016; 18: S0016-5085(16); 00218-3
• 267 Levy RL, Whitehead WE, Von Korff MR. et al Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95: 451-456
• 268 Levy RL, Jones KR, Whitehead WE. et al Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799-804
• 269 Chitkara DK, van Tilburg MA, Blois-Martin N. et al Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 2008; 103: 765-774 ; quiz 775
• 270 Drossman DA, Leserman J, Li Z. et al Effects of coping on health outcome among women with gastrointestinal disorders. Psychosom Med 2000; 62: 309-317
• 271 Jones MP, Wessinger S, Crowell MD. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 474-481
• 272 Drossman DA, Chang L, Bellamy N. et al Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 2011; 106: 1749-1759 ; quiz 1760
• 273 Whitehead WE, Winget C, Fedoravicius AS. et al Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 1982; 27: 202-208
• 274 Tanum L, Malt UF. Personality and physical symptoms in nonpsychiatric patients with functional gastrointestinal disorder. J Psychosom Res 2001; 50: 139-146
• 275 Elsenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2015; 12: 472-485
• 276 Wilpart K, Tornblom H, Svedlund J. et al Coping Skills Are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2017; 15: 1565-1571 e1563
• 277 Keefer L. Behavioural medicine and gastrointestinal disorders: the promise of positive psychology. Nat Rev Gastroenterol Hepatol 2018; 15: 378-386
• 278 Park SH, Videlock EJ, Shih W. et al Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. Neurogastroenterol Motil 2016; 28: 1252-1260
• 279 Jarrett M, Heitkemper M, Cain KC. et al The relationship between psychological distress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 1998; 47: 154-161
• 280 Sibelli A, Chalder T, Everitt H. et al A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med 2016; 46: 3065-3080
• 281 Bennett EJ, Tennant CC, Piesse C. et al Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256-261
• 282 Koloski NA, Jones M, Kalantar J. et al The brain – gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61: 1284-1290
• 283 Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment Pharmacol Ther 2016; 44: 592-600
• 284 Jones MP, Tack J, Van Oudenhove L. et al Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population. Clin Gastroenterol Hepatol 2017; 15: 1014-1020 e1014
• 285 Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988
• 286 Lowe B, Lohse A, Andresen V. et al The Development of Irritable Bowel Syndrome: A Prospective Community-Based Cohort Study. Am J Gastroenterol 2016; 111: 1320-1329
• 287 Blanchard EB, Lackner JM, Jaccard J. et al The role of stress in symptom exacerbation among IBS patients. J Psychosom Res 2008; 64: 119-128
• 288 Gray MA, Chao CY, Staudacher HM. et al Anti-TNFalpha therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases. PLoS One 2018; 13: e0193542
• 289 Holtmann G, Enck P. Stress and Gastrointestinal Motility in Humans: A Review of the Literature. Neurogastroenterol Motil 1991; 3: 245-254
• 290 Mayer EA, Naliboff BD, Chang L. et al V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2001; 280: G519-G524
• 291 Fukudo S. Stress and visceral pain: focusing on irritable bowel syndrome. Pain 2013; 154 (Suppl. 01) S63-S70
• 292 Elsenbruch S, Enck P. The stress concept in gastroenterology: from Selye to today. F1000Res 2017; 6: 2149
• 293 Dickhaus B, Mayer EA, Firooz N. et al Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol 2003; 98: 135-143
• 294 Posserud I, Agerforz P, Ekman R. et al Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102-1108
• 295 Elsenbruch S, Rosenberger C, Bingel U. et al Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010; 139: 1310-1319
• 296 Holtmann G, Singer MV, Kriebel R. et al Differential effects of acute mental stress on interdigestive secretion of gastric acid, pancreatic enzymes, and gastroduodenal motility. Dig Dis Sci 1989; 34: 1701-1707
• 297 Tache Y, Martinez V, Million M. et al Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol Gastrointest Liver Physiol 2001; 280: G173-G177
• 298 Liebregts T, Adam B, Bertel A. et al Psychological stress and the severity of post-inflammatory visceral hyperalgesia. Eur J Pain 2007; 11: 216-222
• 299 Pohl CS, Medland JE, Moeser AJ. Early-life stress origins of gastrointestinal disease: animal models, intestinal pathophysiology, and translational implications. Am J Physiol Gastrointest Liver Physiol 2015; 309: G927-G941
• 300 O’Mahony SM, Clarke G, Dinan TG. et al Irritable Bowel Syndrome and Stress-Related Psychiatric Co-morbidities: Focus on Early Life Stress. Handb Exp Pharmacol 2017; 239: 219-246
• 301 Meerveld BG, Johnson AC. Mechanisms of Stress-induced Visceral Pain. J Neurogastroenterol Motil 2018; 24: 7-18
• 302 Moloney RD, O’Mahony SM, Dinan TG. et al Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry 2015; 6: 15
• 303 Osadchiy V, Martin CR, Mayer EA. The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications. Clin Gastroenterol Hepatol 2019; 17: 322-332
• 304 Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci 2018; 12: 49
• 305 Yarandi SS, Nasseri-Moghaddam S, Mostajabi P. et al Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms. World J Gastroenterol 2010; 16: 1232-1238
• 306 Hammer J, Talley NJ. Value of different diagnostic criteria for the irritable bowel syndrome among men and women. J Clin Gastroenterol 2008; 42: 160-166
• 307 Palsson OS, Whitehead WE, van Tilburg MA. et al Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology 2016; 13: S0016-5085(16); 00180-3
• 308 Costanza CD, Longstreth GF, Liu AL. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol 2004; 2: 395-399
• 309 Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1: 963-965
• 310 Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122: 107-112
• 311 Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome – prognosis and diagnostic safety. A 5-year follow-up study. Scand J Gastroenterol 1985; 20: 415-418
• 312 Sullivan SN. Management of the irritable bowel syndrome: a personal view. J Clin Gastroenterol 1983; 5: 499-502
• 313 Holmes KM, Salter RH. Irritable bowel syndrome – a safe diagnosis?. Br Med J (Clin Res Ed) 1982; 285: 1533-1534
• 314 Jellema P, van der Windt DA, Schellevis FG. et al Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther 2009; 30: 695-706
• 315 Spiegel BM, Farid M, Esrailian E. et al Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105: 848-858
• 316 El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 861-870
• 317 Canavan C, Card T, West J. The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: a cohort study. PLoS One 2014; 9: e106478
• 318 Chang HC, Yen AM, Fann JC. et al Irritable bowel syndrome and the incidence of colorectal neoplasia: a prospective cohort study with community-based screened population in Taiwan. Br J Cancer 2015; 112: 171-176
• 319 Norgaard M, Farkas DK, Pedersen L. et al Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer 2011; 104: 1202-1206
• 320 Wedlake L, A’Hern R, Russell D. et al Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-717
• 321 Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 359-365.e351
• 322 Irvine AJ, Chey WD, Ford AC. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am J Gastroenterol 2017; 112: 65-76
• 323 Ford AC, Chey WD, Talley NJ. et al Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009; 169: 651-658
• 324 Card TR, Siffledeen J, West J. et al An excess of prior irritable bowel syndrome diagnoses or treatments in Celiac disease: evidence of diagnostic delay. Scand J Gastroenterol 2013; 48: 801-807
• 325 Sanchez-Vargas LA, Thomas-Dupont P, Torres-Aguilera M. et al Prevalence of celiac disease and related antibodies in patients diagnosed with irritable bowel syndrome according to the Rome III criteria. A case-control study. Neurogastroenterol Motil 2016; 28: 994-1000
• 326 Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-1482
• 327 Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J 2014; 2: 505-512
• 328 Fukuba N, Ishihara S, Tada Y. et al Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol 2014; 49: 674-680
• 329 Porter CK, Cash BD, Pimentel M. et al Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol 2012; 12: 55
• 330 Guagnozzi D, Arias A, Lucendo AJ. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther 2016; 43: 851-862
• 331 Slattery SA, Niaz O, Aziz Q. et al Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11
• 332 Herve S, Beaugerie L, Bouhnik Y. et al Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study. Neurogastroenterol Motil 2009; 21: 1170-e1102
• 333 Mathur R, Ko A, Hwang LJ. et al Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci 2010; 55: 1085-1089
• 334 Vanner SJ, Depew WT, Paterson WG. et al Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94: 2912-2917
• 335 Whitehead WE, Palsson OS, Feld AD. et al Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006; 24: 137-146
• 336 Patel P, Bercik P, Morgan DG. et al Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol 2015; 50: 816-823
• 337 Ilnyckyj A, Graff LA, Blanchard JF. et al Therapeutic value of a gastroenterology consultation in irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 871-880
• 338 Kaptchuk TJ, Kelley JM, Conboy LA. et al Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003
• 339 Garcia Rodriguez LA, Ruigomez A, Wallander MA. et al Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2000; 35: 306-311
• 340 Eltabbakh GH, Yadav PR, Morgan A. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 1999; 75: 476-479
• 341 Goff BA, Mandel LS, Melancon CH. et al Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291: 2705-2712
• 342 Goff BA, Mandel LS, Drescher CW. et al Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221-227
• 343 Vine MF, Calingaert B, Berchuck A. et al Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol 2003; 90: 75-82
• 344 Friedman GD, Skilling JS, Udaltsova NV. et al Early symptoms of ovarian cancer: a case-control study without recall bias. Fam Pract 2005; 22: 548-553
• 345 Hamilton W, Peters TJ, Bankhead C. et al Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009; 339: b2998
• 346 Behtash N, Ghayouri Azar E, Fakhrejahani F. Symptoms of ovarian cancer in young patients 2 years before diagnosis, a case-control study. Eur J Cancer Care (Engl) 2008; 17: 483-487
• 347 Goff BA, Mandel L, Muntz HG. et al Ovarian carcinoma diagnosis. Cancer 2000; 89: 2068-2075
• 348 Olsen CM, Cnossen J, Green AC. et al Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol 2007; 28: 376-380
• 349 Webb PM, Purdie DM, Grover S. et al Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004; 92: 232-239
• 350 Smith LH, Morris CR, Yasmeen S. et al Ovarian cancer: can we make the clinical diagnosis earlier?. Cancer 2005; 104: 1398-1407
• 351 Minderhoud IM, Oldenburg B, Wismeijer JA. et al IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-474
• 352 Farrokhyar F, Marshall JK, Easterbrook B. et al Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006; 12: 38-46
• 353 Kamp EJ, Kane JS, Ford AC. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 659-668.e651 ; quiz e654-655
• 354 Sanders DS, Carter MJ, Hurlstone DP. et al Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001; 358: 1504-1508
• 355 O’Leary C, Wieneke P, Buckley S. et al Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol 2002; 97: 1463-1467
• 356 Zipser RD, Patel S, Yahya KZ. et al Presentations of adult celiac disease in a nationwide patient support group. Dig Dis Sci 2003; 48: 761-764
• 357 Wilder-Smith CH, Olesen SS, Materna A. et al Fermentable Sugar Ingestion, Gas Production, and Gastrointestinal and Central Nervous System Symptoms in Patients With Functional Disorders. Gastroenterology 2018; 155: 1034-1044 e1036
• 358 Jung KW, Seo M, Cho YH. et al Prevalence of Fructose Malabsorption in Patients With Irritable Bowel Syndrome After Excluding Small Intestinal Bacterial Overgrowth. J Neurogastroenterol Motil 2018; 24: 307-316
• 359 Melchior C, Gourcerol G, Dechelotte P. et al Symptomatic fructose malabsorption in irritable bowel syndrome: A prospective study. United European Gastroenterol J 2014; 2: 131-137
• 360 Varju P, Gede N, Szakacs Z. et al Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterol Motil 2018; 31: e13527
• 361 Ford AC, Spiegel BM, Talley NJ. et al Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-1286
• 362 Ghoshal UC, Srivastava D, Ghoshal U. et al Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol 2014; 26: 753-760
• 363 Rana SV, Sharma S, Kaur J. et al Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion 2012; 85: 243-247
• 364 Valentin N, Camilleri M, Altayar O. et al Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut 2016; 65: 1951-1959
• 365 Carroccio A, Mansueto P, Iacono G. et al Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107: 1898-1906 ; quiz 1907
• 366 Alamo RZ, Quigley EMM. Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches. Curr Opin Gastroenterol 2019; 35: 27-33
• 367 Cremon C, Bellacosa L, Barbaro MR. et al Diagnostic challenges of symptomatic uncomplicated diverticular disease. Minerva Gastroenterol Dietol 2017; 63: 119-129
• 368 Jarbrink-Sehgal ME, Andreasson A, Talley NJ. et al Symptomatic Diverticulosis Is Characterized By Loose Stools. Clin Gastroenterol Hepatol 2016; 14: 1763-1770 e1761
• 369 Tursi A, Elisei W, Picchio M. et al Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. J Clin Gastroenterol 2015; 49: 218-221
• 370 Tursi A, Elisei W, Giorgetti G. et al Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis. Minerva Gastroenterol Dietol 2011; 57: 247-255
• 371 Ierardi E, Meucci G, Hassan C. et al Tumour necrosis factor alpha in segmental colitis associated with diverticula. Dig Dis Sci 2008; 53: 1865-1868
• 372 Schomacker ML, Hansen KE, Ramlau-Hansen CH. et al Is endometriosis associated with irritable bowel syndrome? A cross-sectional study. Eur J Obstet Gynecol Reprod Biol 2018; 231: 65-69
• 373 Ek M, Roth B, Nilsson PM. et al Characteristics of endometriosis: A case-cohort study showing elevated IgG titers against the TSH receptor (TRAb) and mental comorbidity. Eur J Obstet Gynecol Reprod Biol 2018; 231: 8-14
• 374 Vigano D, Zara F, Usai P. Irritable bowel syndrome and endometriosis: New insights for old diseases. Dig Liver Dis 2018; 50: 213-219
• 375 Lee CE, Yong PJ, Williams C. et al Factors Associated with Severity of Irritable Bowel Syndrome Symptoms in Patients with Endometriosis. J Obstet Gynaecol Can 2018; 40: 158-164
• 376 Moore JS, Gibson PR, Perry RE. et al Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet. Aust N Z J Obstet Gynaecol 2017; 57: 201-205
• 377 Ek M, Roth B, Ekstrom P. et al Gastrointestinal symptoms among endometriosis patients – A case-cohort study. BMC Womens Health 2015; 15: 59
• 378 Wu CY, Chang WP, Chang YH. et al The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study. Int J Colorectal Dis 2015; 30: 907-912
• 379 Chey WD, Nojkov B, Rubenstein JH. et al The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010; 105: 859-865
• 380 Gu HX, Zhang YL, Zhi FC. et al Organic colonic lesions in 3332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case--control study. Int J Colorectal Dis 2011; 26: 935-940
• 381 Waugh N, Cummins E, Royle P. et al Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013; 17: xv-xix, 1-211
• 382 Menees SB, Powell C, Kurlander J. et al A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110: 444-454
• 383 Zhou XL, Xu W, Tang XX. et al Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol 2014; 14: 121
• 384 Emmanuel A, Landis D, Peucker M. et al Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. Frontline Gastroenterol 2016; 7: 275-282
• 385 Sood R, Gracie DJ, Law GR. et al Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015; 42: 491-503
• 386 Vernia P, Marinaro V, Argnani F. et al Self-reported milk intolerance in irritable bowel syndrome: what should we believe?. Clin Nutr 2004; 23: 996-1000
• 387 Wilder-Smith CH, Olesen SS, Materna A. et al Repeatability and effect of blinding of fructose breath tests in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2019; 31: e13497
• 388 Chen B, Kim JJ, Zhang Y. et al Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol 2018; 53: 807-818
• 389 Fernandez-Banares F, Esteve M, Salas A. et al Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007; 102: 2520-2528
• 390 National Institute for Health and Clinical Excellence N. Clinical Practice Guideline on Irritable Bowel Syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. 2008 www.nice.org.uk
• 391 Bouin M, Plourde V, Boivin M. et al Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777
• 392 Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115: 1263-1271
• 393 Lembo AJ, Neri B, Tolley J. et al Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 834-842
• 394 Aerssens J, Camilleri M, Talloen W. et al Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 194-205
• 395 Mujagic Z, Tigchelaar EF, Zhernakova A. et al A novel biomarker panel for irritable bowel syndrome and the application in the general population. Sci Rep 2016; 6: 26420
• 396 Parsons K, Goepp J, Dechairo B. et al Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study. Glob Adv Health Med 2014; 3: 25-32
• 397 Pimentel M, Morales W, Rezaie A. et al Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 2015; 10: e0126438
• 398 Whitehead WE, Palsson OS, Simren M. Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. Neurogastroenterol Motil 2016; 28: 783-792
• 399 DuPont HL. Persistent Diarrhea: A Clinical Review. JAMA 2016; 315: 2712-2723
• 400 Duplessis CA, Gutierrez RL, Porter CK. Review: chronic and persistent diarrhea with a focus in the returning traveler. Trop Dis Travel Med Vaccines 2017; 3: 9
• 401 El-Abassi R, Soliman MY, Williams F. et al Whipple’s disease. J Neurol Sci 2017; 377: 197-206
• 402 Vazquez Guillamet LJ, Saul Z, Miljkovich G. et al Strongyloides Stercoralis Infection Among Human Immunodeficiency Virus (HIV)-Infected Patients in the United States of America: A Case Report and Review of Literature. Am J Case Rep 2017; 18: 339-346
• 403 Raynaud L, Delbac F, Broussolle V. et al Identification of Encephalitozoon intestinalis in travelers with chronic diarrhea by specific PCR amplification. J Clin Microbiol 1998; 36: 37-40
• 404 Enck P, Mazurak N. Dysbiosis in Functional Bowel Disorders. Ann Nutr Metab 2018; 72: 296-306
• 405 Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C. et al A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther 2018; 35: 289-310
• 406 Simren M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol 2018; 15: 589-605
• 407 Claesson MJ, Clooney AG, O’Toole PW. A clinician’s guide to microbiome analysis. Nat Rev Gastroenterol Hepatol 2017; 14: 585-595
• 408 Valeur J, Smastuen MC, Knudsen T. et al Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome. Dig Dis Sci 2018; 63: 429-436
• 409 Bellinghausen I, Weigmann B, Zevallos V. et al Wheat amylase-trypsin inhibitors exacerbate intestinal and airway allergic immune responses in humanized mice. J Allergy Clin Immunol 2019; 143: 201-212 e204
• 410 Bohn L, Storsrud S, Tornblom H. et al Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013; 108: 634-641
• 411 Bischoff S, Crowe SE. Gastrointestinal food allergy: new insights into pathophysiology and clinical perspectives. Gastroenterology 2005; 128: 1089-1113
• 412 Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu Rev Med 2009; 60: 261-277
• 413 DGAKI. Leitlinien für Diagnostik und Therapie Allergologie und klinische Immunologie. AWMF-Online.
• 414 Keller J, Franke A, Storr M. et al [Clinically relevant breath tests in gastroenterological diagnostics – recommendations of the German Society for Neurogastroenterology and Motility as well as the German Society for Digestive and Metabolic Diseases]. Z Gastroenterol 2005; 43: 1071-1090
• 415 Bengtsson M, Ulander K, Borgdal EB. et al A course of instruction for women with irritable bowel syndrome. Patient Educ Couns 2006; 62: 118-125
• 416 Monsbakken KW, Vandvik PO, Farup PG. The value of a general therapeutic approach in subjects with irritable bowel syndrome. Aliment Pharmacol Ther 2005; 21: 21-27
• 417 Saito YA, Prather CM, Van Dyke CT. et al Effects of multidisciplinary education on outcomes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 576-584
• 418 O’Sullivan MA, Mahmud N, Kelleher DP. et al Patient knowledge and educational needs in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2000; 12: 39-43
• 419 Felber J, Aust D, Baas S. et al [Results of a S2k-Consensus Conference of the German Society of Gastroenterolgy, Digestive- and Metabolic Diseases (DGVS) in conjunction with the German Coeliac Society (DZG) regarding coeliac disease, wheat allergy and wheat sensitivity]. Z Gastroenterol 2014; 52: 711-743
• 420 Ortolani C, Pastorello EA. Food allergies and food intolerances. Best Pract Res Clin Gastroenterol 2006; 20: 467-483
• 421 Shepherd SJ, Parker FC, Muir JG. et al Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008; 6: 765-771
• 422 Choi YK, Kraft N, Zimmerman B. et al Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol 2008; 42: 233-238
• 423 Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc 2006; 106: 1631-1639
• 424 Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome – etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667-672
• 425 Goldstein R, Braverman D, Stankiewicz H. Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints. Isr Med Assoc J 2000; 2: 583-587
• 426 Zar S, Mincher L, Benson MJ. et al Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol 2005; 40: 800-807
• 427 Zar S, Benson MJ, Kumar D. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 1550-1557
• 428 Atkinson W, Sheldon TA, Shaath N. et al Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459-1464
• 429 Reese I, Ballmer-Weber B, Beyer K. et al German guideline for the management of adverse reactions to ingested histamine: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SGAI). Allergo J Int 2017; 26: 72-79
• 430 Stapel SO, Asero R, Ballmer-Weber BK. et al Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008; 63: 793-796
• 431 Ford RP. The gluten syndrome: a neurological disease. Med Hypotheses 2009; 73: 438-440
• 432 Zanwar VG, Pawar SV, Gambhire PA. et al Symptomatic improvement with gluten restriction in irritable bowel syndrome: a prospective, randomized, double blinded placebo controlled trial. Intest Res 2016; 14: 343-350
• 433 Catassi C, Elli L, Bonaz B. et al Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts’ Criteria. Nutrients 2015; 7: 4966-4977
• 434 Biesiekierski JR, Peters SL, Newnham ED. et al No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328.e321-323
• 435 Lionetti E, Pulvirenti A, Vallorani M. et al Re-challenge Studies in Non-celiac Gluten Sensitivity: A Systematic Review and Meta-Analysis. Front Physiol 2017; 8: 621
• 436 Vazquez-Roque MI, Camilleri M, Smyrk T. et al A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903-911.e903
• 437 Sattler J, Hafner D, Klotter HJ. et al Food-induced histaminosis as an epidemiological problem: plasma histamine elevation and haemodynamic alterations after oral histamine administration and blockade of diamine oxidase (DAO). Agents Actions 1988; 23: 361-365
• 438 Music E, Korosec P, Silar M. et al Serum diamine oxidase activity as a diagnostic test for histamine intolerance. Wien Klin Wochenschr 2013; 125: 239-243
• 439 Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr 2007; 85: 1185-1196
• 440 Hausteiner-Wiehle C, Schäfert R, Sattel H. et al S3 Leitlinie „Funktionelle Körperbeschwerden“. 2018
• 441 Hermann-Lingen C, Buss U, Snaith RP. Hospital anxiety and depression scale – Deutsche Version (HADS-D). Göttingen: Hogrefe; 1995
• 442 Löwe B, Spitzer R, Zipfel S. et al Gesundheitsfragebogen für Patienten (PHQ-D). Manual und Testunterlagen. Karlsruhe: Pfitzer; 2002
• 443 Palsson OS, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol Hepatol 2013; 11: 208-216 ; quiz e222-203
• 444 Ng QX, Soh AYS, Loke W. et al Systematic review with meta-analysis: The association between post-traumatic stress disorder and irritable bowel syndrome. J Gastroenterol Hepatol 2019; 34: 68-73
• 445 Afari N, Ahumada SM, Wright LJ. et al Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med 2014; 76: 2-11
• 446 Fischer G, Riedesser P. Lehrbuch der Psychotraumatologie. 2009
• 447 Hinson VK, Haren WB. Psychogenic movement disorders. Lancet Neurol 2006; 5: 695-700
• 448 Connor FL, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and management. Gastroenterology 2006; 130: S29-36
• 449 Stanghellini V, Cogliandro RF, de Giorgio R. et al Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil 2007; 19: 440-452
• 450 Seidl H, Pehl C, Schepp W. et al [Chronic intestinal pseudo-obstruction – review and update 2008]. Z Gastroenterol 2008; 46: 704-711
• 451 Kessmann J. Hirschsprung’s disease: diagnosis and management. Am Fam Physician 2006; 74: 1319-1322
• 452 De Giorgio R, Guerrini S, Barbara G. et al Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004; 126: 1872-1883
• 453 Di Nardo G, Blandizzi C, Volta U. et al Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 2008; 28: 25-42
• 454 Knowles CH, De Giorgio R, Kapur RP. et al Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group. Acta Neuropathol 2009; 118: 271-301
• 455 Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 2006; 19: 1638-1645
• 456 Eisen GM, Baron TH, Dominitz JA. et al Acute colonic pseudo-obstruction. Gastrointest Endosc 2002; 56: 789-792
• 457 Saunders MD. Acute colonic pseudo-obstruction. Gastrointest Endosc Clin N Am 2007; 17: 341-360, vi-vii
• 458 Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2005; 22: 917-925
• 459 Gladman MA, Knowles CH. Novel concepts in the diagnosis, pathophysiology and management of idiopathic megabowel. Colorectal Dis 2008; 10: 531-538 ; discussion 538-540
• 460 Martucciello G. Hirschsprung’s disease, one of the most difficult diagnoses in pediatric surgery: a review of the problems from clinical practice to the bench. Eur J Pediatr Surg 2008; 18: 140-149
• 461 Bassotti G, Villanacci V. Slow transit constipation: a functional disorder becomes an enteric neuropathy. World J Gastroenterol 2006; 12: 4609-4613
• 462 Bharucha AE. Constipation. Best Pract Res Clin Gastroenterol 2007; 21: 709-731
• 463 Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am 2007; 36: 687-711, x
• 464 Spiller R. Role of motility in chronic diarrhoea. Neurogastroenterol Motil 2006; 18: 1045-1055
• 465 de Lorijn F, Kremer LC, Reitsma JB. et al Diagnostic tests in Hirschsprung disease: a systematic review. J Pediatr Gastroenterol Nutr 2006; 42: 496-505
• 466 Rao SS, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: a systematic review. Am J Gastroenterol 2005; 100: 1605-1615
• 467 Camilleri M, Bharucha AE, di Lorenzo C. et al American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil 2008; 20: 1269-1282
• 468 Andresen V, Lowe B, Broicher W. et al Post-infectious irritable bowel syndrome (PI-IBS) after infection with Shiga-like toxin-producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow-up. United European Gastroenterol J 2016; 4: 121-131
• 469 Klem F, Wadhwa A, Prokop LJ. et al Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 152: 1042-1054 e1041
• 470 Aiarzaguena JM, Grandes G, Gaminde I. et al A randomized controlled clinical trial of a psychosocial and communication intervention carried out by GPs for patients with medically unexplained symptoms. Psychol Med 2007; 37: 283-294
• 471 van Dulmen AM, Fennis JF, Mokkink HG. et al The relationship between complaint-related cognitions in referred patients with irritable bowel syndrome and subsequent health care seeking behaviour in primary care. Fam Pract 1996; 13: 12-17
• 472 Thompson WG, Heaton KW, Smyth GT. et al Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 78-82
• 473 Bertram S, Kurland M, Lydick E. et al The patient’s perspective of irritable bowel syndrome. J Fam Pract 2001; 50: 521-525
• 474 Bijkerk CJ, de Wit NJ, Stalman WA. et al Irritable bowel syndrome in primary care: the patients’ and doctors’ views on symptoms, etiology and management. Can J Gastroenterol 2003; 17: 363-368 ; quiz 405-366
• 475 Halpert A, Dalton CB, Palsson O. et al Irritable bowel syndrome patients’ ideal expectations and recent experiences with healthcare providers: a national survey. Dig Dis Sci 2010; 55: 375-383
• 476 Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur J Gastroenterol Hepatol 2004; 16: 1161-1166
• 477 Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237-247
• 478 Spiegel BM, Hays RD, Bolus R. et al Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014; 109: 1804-1814
• 479 Schafer SK, Weidner KJ, Hoppner J. et al Design and validation of a German version of the GSRS-IBS – an analysis of its psychometric quality and factorial structure. BMC Gastroenterol 2017; 17: 139
• 480 Koloski NA, Jones M, Hammer J. et al The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting. Dig Dis Sci 2017; 62: 1913-1922
• 481 Ringstrom G, Storsrud S, Posserud I. et al Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study. Eur J Gastroenterol Hepatol 2010; 22: 420-428
• 482 Labus J, Gupta A, Gill HK. et al Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Aliment Pharmacol Ther 2013; 37: 304-315
• 483 Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc 2018; 93: 1858-1872
• 484 Cashman MD, Martin DK, Dhillon S. et al Irritable Bowel Syndrome: A Clinical Review. Curr Rheumatol Rev 2016; 12: 13-26
• 485 Laird KT, Tanner-Smith EE, Russell AC. et al Short-term and Long-term Efficacy of Psychological Therapies for Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 937-947.e934
• 486 Tillisch K, Labus JS, Naliboff BD. et al Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 896-904
• 487 Westerberg L, Theorell T. Working conditions and family situation in relation to functional gastrointestinal disorders. The Swedish Dyspepsia Project. Scand J Prim Health Care 1997; 15: 76-81
• 488 Kang SH, Choi SW, Lee SJ. et al The effects of lifestyle modification on symptoms and quality of life in patients with irritable bowel syndrome: a prospective observational study. Gut Liver 2011; 5: 472-477
• 489 Ohlsson B, Manjer J. Physical inactivity during leisure time and irregular meals are associated with functional gastrointestinal complaints in middle-aged and elder subjects. Scand J Gastroenterol 2016; 51: 1299-1307
• 490 Johannesson E, Ringstrom G, Abrahamsson H. et al Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol 2015; 21: 600-608
• 491 Johannesson E, Simren M, Strid H. et al Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106: 915-922
• 492 Liegl G, Plessen CY, Leitner A. et al Guided self-help interventions for irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2015; 27: 1209-1221
• 493 Zheng SC, Gong H, Wang YP. et al Health education program improves QOL in students with irritable bowel syndrome after the Wenchuan earthquake: a five-year multi-center study. BMC Gastroenterol 2018; 18: 119
• 494 Eugenio MD, Jun SE, Cain KC. et al Comprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioning. Dig Dis Sci 2012; 57: 1636-1646
• 495 Everitt H, Moss-Morris R, Sibelli A. et al Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol 2013; 13: 68
• 496 Heitkemper MM, Jarrett ME, Levy RL. et al Self-management for women with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 585-596
• 497 Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy for irritable bowel syndrome. Behav Res Ther 2009; 47: 797-802
• 498 Ljotsson B, Hedman E, Andersson E. et al Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial. Am J Gastroenterol 2011; 106: 1481-1491
• 499 Ljotsson B, Andersson G, Andersson E. et al Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterol 2011; 11: 110
• 500 Ljotsson B, Falk L, Vesterlund AW. et al Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome--a randomized controlled trial. Behav Res Ther 2010; 48: 531-539
• 501 Moss-Morris R, McAlpine L, Didsbury LP. et al A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med 2010; 40: 85-94
• 502 Oerlemans S, van Cranenburgh O, Herremans PJ. et al Intervening on cognitions and behavior in irritable bowel syndrome: A feasibility trial using PDAs. J Psychosom Res 2011; 70: 267-277
• 503 Jarrett ME, Cain KC, Burr RL. et al Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. Am J Gastroenterol 2009; 104: 3004-3014
• 504 Beatty L, Lambert S. A systematic review of internet-based self-help therapeutic interventions to improve distress and disease-control among adults with chronic health conditions. Clin Psychol Rev 2013; 33: 609-622
• 505 Flik CE, van Rood YR, de Wit NJ. Systematic review: knowledge and educational needs of patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2015; 27: 367-371
• 506 Ringstrom G, Storsrud S, Simren M. A comparison of a short nurse-based and a long multidisciplinary version of structured patient education in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2012; 24: 950-957
• 507 Lakhan SE, Schofield KL. Mindfulness-based therapies in the treatment of somatization disorders: a systematic review and meta-analysis. PLoS One 2013; 8: e71834
• 508 O’Keeffe M, Jansen C, Martin L. et al Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30
• 509 Moayyedi P, Quigley EM, Lacy BE. et al The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. Clin Transl Gastroenterol 2015; 6: e107
• 510 Hughes PA, Zola H, Penttila IA. et al Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?. Am J Gastroenterol 2013; 108: 1066-1074
• 511 Ligaarden SC, Lydersen S, Farup PG. Diet in subjects with irritable bowel syndrome: a cross-sectional study in the general population. BMC Gastroenterol 2012; 12: 61
• 512 Nwosu BU, Maranda L, Candela N. Vitamin D status in pediatric irritable bowel syndrome. PLoS One 2017; 12: e0172183
• 513 Manz M, Meier R. [Pharmacologic treatments of transit disorders]. Ther Umsch 2007; 64: 227-232
• 514 Zuckerman MJ. The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations. J Clin Gastroenterol 2006; 40: 104-108
• 515 Rao SS, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41: 1256-1270
• 516 McEligot AJ, Gilpin EA, Rock CL. et al High dietary fiber consumption is not associated with gastrointestinal discomfort in a diet intervention trial. J Am Diet Assoc 2002; 102: 549-551
• 517 Singh N, Makharia GK, Joshi YK. Dietary survey and total dietary fiber intake in patients with irritable bowel syndrome attending a tertiary referral hospital. Indian J Gastroenterol 2008; 27: 66-70
• 518 Anti M, Pignataro G, Armuzzi A. et al Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology 1998; 45: 727-732
• 519 Bijkerk CJ, Muris JW, Knottnerus JA. et al Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 245-251
• 520 Parisi GC, Zilli M, Miani MP. et al High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci 2002; 47: 1697-1704
• 521 Nagarajan N, Morden A, Bischof D. et al The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2015; 27: 1002-1010
• 522 Moayyedi P, Quigley EM, Lacy BE. et al The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1367-1374
• 523 Hongisto SM, Paajanen L, Saxelin M. et al A combination of fibre-rich rye bread and yoghurt containing Lactobacillus GG improves bowel function in women with self-reported constipation. Eur J Clin Nutr 2006; 60: 319-324
• 524 Tabas G, Beaves M, Wang J. et al Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99: 914-920
• 525 Quartero AO, Meineche-Schmidt V, Muris J. et al Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005:CD003460
• 526 Hebden JM, Blackshaw E, D’Amato M. et al Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol 2002; 97: 2315-2320
• 527 McRorie J, Kesler J, Bishop L. et al Effects of wheat bran and Olestra on objective measures of stool and subjective reports of GI symptoms. Am J Gastroenterol 2000; 95: 1244-1252
• 528 Zumarraga L, Levitt MD, Suarez F. Absence of gaseous symptoms during ingestion of commercial fibre preparations. Aliment Pharmacol Ther 1997; 11: 1067-1072
• 529 Ong DK, Mitchell SB, Barrett JS. et al Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366-1373
• 530 Austin GL, Dalton CB, Hu Y. et al A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 706-708.e701
• 531 Eswaran SL, Chey WD, Han-Markey T. et al A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol 2016; 111: 1824-1832
• 532 Halmos EP, Power VA, Shepherd SJ. et al A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75.e65
• 533 Altobelli E, Del Negro V, Angeletti PM. et al Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients 2017; 9: 940
• 534 Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 2016; 55: 897-906
• 535 Varju P, Farkas N, Hegyi P. et al Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: A meta-analysis of clinical studies. PLoS One 2017; 12: e0182942
• 536 Schumann D, Klose P, Lauche R. et al Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Nutrition 2018; 45: 24-31
• 537 Pols RG, Battersby MW. Coordinated care in the management of patients with unexplained physical symptoms: depression is a key issue. Med J Aust 2008; 188: S133-S137
• 538 Gerson CD, Gerson MJ. A collaborative health care model for the treatment of irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1: 446-452
• 539 Zijdenbos IL, de Wit NJ, van der Heijden GJ. et al Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009:CD006442
• 540 Ford AC, Lacy BE, Harris LA. et al Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol 2019; 114: 21-39
• 541 Li L, Xiong L, Zhang S. et al Cognitive-behavioral therapy for irritable bowel syndrome: a meta-analysis. J Psychosom Res 2014; 77: 1-12
• 542 Altayar O, Sharma V, Prokop LJ. et al Psychological therapies in patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Gastroenterol Res Pract 2015; 2015: 549308
• 543 Schaefert R, Klose P, Moser G. et al Efficacy, tolerability, and safety of hypnosis in adult irritable bowel syndrome: systematic review and meta-analysis. Psychosom Med 2014; 76: 389-398
• 544 Moser G, Tragner S, Gajowniczek EE. et al Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2013; 108: 602-609
• 545 Schaefert R, Hausteiner-Wiehle C, Hauser W. et al Non-specific, functional, and somatoform bodily complaints. Dtsch Arztebl Int 2012; 109: 803-813
• 546 Menees SB, Maneerattannaporn M, Kim HM. et al The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35 ; quiz 36
• 547 Schoenfeld P, Pimentel M, Chang L. et al Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014; 39: 1161-1168
• 548 Pimentel M, Lembo A, Chey WD. et al Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32
• 549 Lembo A, Pimentel M, Rao SS. et al Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 2016; 151: 1113-1121
• 550 Bischoff S. Probiotika, Präbiotika. Synbiotika. Thieme; 2009
• 551 Ford AC, Harris LA, Lacy BE. et al Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018; 48: 1044-1060
• 552 Dimidi E, Christodoulides S, Fragkos KC. et al The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014; 100: 1075-1084
• 553 Ford AC, Quigley EM, Lacy BE. et al Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547-1561 ; quiz 1546, 1562
• 554 Nikfar S, Mozafari S, Didari T. et al Effectiveness Of Probiotics In Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis. Value Health 2014; 17: A363
• 555 Didari T, Mozaffari S, Nikfar S. et al Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 2015; 21: 3072-3084
• 556 Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med 2015; 54: 243-249
• 557 Koppen IJ, Benninga MA, Tabbers MM. Is There A Role for Pre-, Pro- and Synbiotics in the Treatment of Functional Constipation in Children? A Systematic Review. J Pediatr Gastroenterol Nutr 2016; 63 (Suppl. 01) S27-S35
• 558 Zhang Y, Li L, Guo C. et al Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol 2016; 16: 62
• 559 Cayzeele-Decherf A, Pelerin F, Leuillet S. et al Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol 2017; 23: 336-344
• 560 Sebastian Domingo JJ. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol 2017; 40: 417-429
• 561 Han K, Wang J, Seo JG. et al Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. J Gastroenterol 2017; 52: 432-443
• 562 Pedersen N, Andersen NN, Vegh Z. et al Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 2014; 20: 16215-16226
• 563 Yeun Y, Lee J. Effect of a double-coated probiotic formulation on functional constipation in the elderly: a randomized, double blind, controlled study. Arch Pharm Res 2015; 38: 1345-1350
• 564 Abbas Z, Yakoob J, Jafri W. et al Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 2014; 26: 630-639
• 565 Lorenzo-Zuniga V, Llop E, Suarez C. et al I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 2014; 20: 8709-8716
• 566 Ludidi S, Jonkers DM, Koning CJ. et al Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014; 26: 705-714
• 567 Sisson G, Ayis S, Sherwood RA. et al Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Aliment Pharmacol Ther 2014; 40: 51-62
• 568 Yoon JS, Sohn W, Lee OY. et al Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 2014; 29: 52-59
• 569 Choi CH, Kwon JG, Kim SK. et al Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil 2015; 27: 705-716
• 570 Fuke N, Aizawa K, Suganuma H. et al Effect of combined consumption of Lactobacillus brevis KB290 and beta-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr 2017; 68: 973-986
• 571 Faghihi AH, Agah S, Masoudi M. et al Efficacy of Probiotic Escherichia coli Nissle 1917 in Patients with Irritable Bowel Syndrome: a Double Blind Placebo-controlled Randomized Trial. Acta Med Indones 2015; 47: 201-208
• 572 Hod K, Sperber AD, Ron Y. et al A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil 2017; 29
• 573 Jafari E, Vahedi H, Merat S. et al Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med 2014; 17: 466-470
• 574 Lyra A, Hillila M, Huttunen T. et al Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol 2016; 22: 10631-10642
• 575 Majeed M, Nagabhushanam K, Natarajan S. et al Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 2016; 15: 21
• 576 Mezzasalma V, Manfrini E, Ferri E. et al A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. Biomed Res Int 2016; 2016: 4740907
• 577 Moreira TR, Leonhardt D, Conde SR. Influence of drinking a probiotic fermented milk beverage containing Bifidobacterium animalis on the symptoms of constipation. Arquivos De Gastroenterologia 2017; 54: 206-210
• 578 Nobutani K, Sawada D, Fujiwara S. et al The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. J Appl Microbiol 2017; 122: 212-224
• 579 Ojetti V, Ianiro G, Tortora A. et al The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis 2014; 23: 387-391
• 580 Pineton de Chambrun G, Neut C, Chau A. et al A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015; 47: 119-124
• 581 Pinto-Sanchez MI, Hall GB, Ghajar K. et al Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology 2017; 153: 448-459 e448
• 582 Ringel-Kulka T, McRorie J, Ringel Y. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Am J Gastroenterol 2017; 112: 145-151
• 583 Shavakhi A, Minakari M, Farzamnia S. et al The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res 2014; 3: 140
• 584 Spiller R, Pelerin F, Cayzeele Decherf A. et al Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol J 2016; 4: 353-362
• 585 Stevenson C, Blaauw R, Fredericks E. et al Randomized clinical trial: effect of Lactobacillus plantarum 299v on symptoms of irritable bowel syndrome. Nutrition 2014; 30: 1151-1157
• 586 Thijssen AY, Clemens CH, Vankerckhoven V. et al Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2016; 28: 8-14
• 587 Yoon H, Park YS, Lee DH. et al Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr 2015; 57: 129-134
• 588 O’Mahony L, McCarthy J, Kelly P. et al Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
• 589 Whorwell PJ, Altringer L, Morel J. et al Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-1590
• 590 Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 2013; 4: 201-211
• 591 Guyonnet D, Chassany O, Ducrotte P. et al Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486
• 592 Marteau P, Cuillerier E, Meance S. et al Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002; 16: 587-593
• 593 Guglielmetti S, Mora D, Gschwender M. et al Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123-1132
• 594 Nobaek S, Johansson ML, Molin G. et al Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238
• 595 Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147
• 596 Sen S, Mullan MM, Parker TJ. et al Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-2620
• 597 Ducrotte P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18: 4012-4018
• 598 Murakami K, Habukawa C, Nobuta Y. et al The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med 2012; 6: 16
• 599 Sinn DH, Song JH, Kim HJ. et al Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714-2718
• 600 Niv E, Naftali T, Hallak R. et al The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-931
• 601 Koebnick C, Wagner I, Leitzmann P. et al Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003; 17: 655-659
• 602 Mazlyn MM, Nagarajah LH, Fatimah A. et al Effects of a probiotic fermented milk on functional constipation: a randomized, double-blind, placebo-controlled study. J Gastroenterol Hepatol 2013; 28: 1141-1147
• 603 Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009; 31: 655-659
• 604 Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009; 121: 119-124
• 605 Enck P, Zimmermann K, Menke G. et al Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009; 47: 209-214
• 606 Kim HJ, Vazquez Roque MI, Camilleri M. et al A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696
• 607 Kajander K, Myllyluoma E, Rajilic-Stojanovic M. et al Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48-57
• 608 Williams EA, Stimpson J, Wang D. et al Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 97-103
• 609 Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-1412
• 610 Basturk A, Artan R, Yilmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol 2016; 27: 439-443
• 611 Silk DB, Davis A, Vulevic J. et al Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-518
• 612 Corinaldesi R, Stanghellini V, Cremon C. et al Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-252
• 613 Dorofeyev AE, Kiriyan EA, Vasilenko IV. et al Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol 2011; 4: 141-153
• 614 Barbara G, Cremon C, Annese V. et al Randomised controlled trial of mesalazine in IBS. Gut 2016; 65: 82-90
• 615 Lam C, Tan W, Leighton M. et al A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut 2016; 65: 91-99
• 616 Tuteja AK, Fang JC, Al-Suqi M. et al Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study. Scand J Gastroenterol 2012; 47: 1159-1164
• 617 Balemans D, Mondelaers SU, Cibert-Goton V. et al Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS. Sci Rep 2017; 7: 13606
• 618 Balemans D, Aguilera-Lizarraga J, Florens MV. et al Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2019; 316: G338-G349
• 619 Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut 2016; 65: 155-168
• 620 Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014; 48: 505-512
• 621 Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 2016; 61: 560-571
• 622 Merat S, Khalili S, Mostajabi P. et al The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390
• 623 Liu JP, Yang M, Liu YX. et al Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006:CD004116
• 624 Shi J, Tong Y, Shen JG. et al Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 2008; 14: 454-462
• 625 Bortolotti M, Porta S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig Dis Sci 2011; 56: 3288-3295
• 626 Brinkhaus B, Hentschel C, Von Keudell C. et al Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Scand J Gastroenterol 2005; 40: 936-943
• 627 Chen C, Tao C, Liu Z. et al A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Phytother Res 2015; 29: 1822-1827
• 628 Davis K, Philpott S, Kumar D. et al Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract 2006; 60: 1080-1086
• 629 Ko SJ, Han G, Kim SK. et al Effect of korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2013; 2013: 824605
• 630 Lauche R, Kumar S, Hallmann J. et al Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial. Complement Ther Med 2016; 26: 171-177
• 631 Madisch A, Holtmann G, Plein K. et al Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19: 271-279
• 632 Van Tilburg MAL, Palsson OS, Ringel Y. et al Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complementary Therapies in Medicine 2014; 22: 17-20
• 633 Saito YA, Rey E, Almazar-Elder AE. et al A randomized, double-blind, placebo-controlled trial of St John’s wort for treating irritable bowel syndrome. Am J Gastroenterol 2010; 105: 170-177
• 634 Sallon S, Ben-Arye E, Davidson R. et al A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002; 65: 161-171
• 635 Lauche R, Janzen A, Ludtke R. et al Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome – A Randomized Controlled Cross-Over Trial. Digestion 2015; 92: 22-31
• 636 Schumann D, Anheyer D, Lauche R. et al Effect of Yoga in the Therapy of Irritable Bowel Syndrome: A Systematic Review. Clin Gastroenterol Hepatol 2016; 14: 1720-1731
• 637 Evans S, Lung KC, Seidman LC. et al Iyengar yoga for adolescents and young adults with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2014; 59: 244-253
• 638 Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369: 946-955
• 639 Brands MM, Purperhart H, Deckers-Kocken JM. A pilot study of yoga treatment in children with functional abdominal pain and irritable bowel syndrome. Complement Ther Med 2011; 19: 109-114
• 640 Shahabi L, Naliboff BD, Shapiro D. Self-regulation evaluation of therapeutic yoga and walking for patients with irritable bowel syndrome: a pilot study. Psychol Health Med 2016; 21: 176-188
• 641 Manheimer E, Cheng K, Wieland LS. et al Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012:Cd005111
• 642 Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2014; 20: 1871-1877
• 643 Park JW, Lee BH, Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complement Altern Med 2013; 13: 247
• 644 Tang B, Zhang J, Yang Z. et al Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2016; 2016: 5105108
• 645 Bian Z, Wu T, Liu L. et al Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med 2006; 12: 401-407
• 646 Li Q, Liu F, Hou Z. et al Treatment of constipation-predominant irritable bowel syndrome by focusing on the liver in terms of Traditional Chinese Medicine: a meta-analysis. J Tradit Chin Med 2013; 33: 562-571
• 647 Xiao Y, Liu Y, Huang S. et al The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome: a meta-analysis of randomized, double-blind, placebo-controlled trials. PLoS One 2015; 10: e0122397
• 648 Oka T, Okumi H, Nishida S. et al Effects of Kampo on functional gastrointestinal disorders. Biopsychosoc Med 2014; 8: 5
• 649 Peckham EJ, Nelson EA, Greenhalgh J. et al Homeopathy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2013:Cd009710
• 650 Park SH, Han KS, Kang CB. Relaxation Therapy for Irritable Bowel Syndrome: A Systematic Review. Asian Nurs Res (Korean Soc Nurs Sci) 2014; 8: 182-192
• 651 Dobbin A, Dobbin J, Ross SC. et al Randomised controlled trial of brief intervention with biofeedback and hypnotherapy in patients with refractory irritable bowel syndrome. J R Coll Physicians Edinb 2013; 43: 15-23
• 652 Tovey P. A single-blind trial of reflexology for irritable bowel syndrome. Br J Gen Pract 2002; 52: 19-23
• 653 Aucoin M, Lalonde-Parsi MJ, Cooley K. Mindfulness-based therapies in the treatment of functional gastrointestinal disorders: a meta-analysis. Evid Based Complement Alternat Med 2014; 2014: 140724
• 654 van Tilburg MA, Palsson OS, Ringel Y. et al Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complement Ther Med 2014; 22: 17-20
• 655 Vejdani R, Shalmani HR, Mir-Fattahi M. et al The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study. Dig Dis Sci 2006; 51: 1501-1507
• 656 Daley AJ, Grimmett C, Roberts L. et al The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med 2008; 29: 778-782
• 657 Dorn SD. Systematic review: self-management support interventions for irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 513-521
• 658 Xiao Y, Liu Y, Huang S. et al The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome:A meta-analysis of randomized, double-blind, placebo-controlled trials. PLoS ONE 2015; 10: e0122397
• 659 Zhang W, Sun JH, Pei LX. et al Traditional Chinese medicine for treatment of irritable bowel syndrome: An overview of systematic reviews and Metaanalyses. World Chinese Journal of Digestology 2014; 22: 1747-1755
• 660 Kanazawa M, Fukudo S. Effects of fasting therapy on irritable bowel syndrome. Int J Behav Med 2006; 13: 214-220
• 661 Muller A, Franke H, Resch KL. et al Effectiveness of osteopathic manipulative therapy for managing symptoms of irritable bowel syndrome: a systematic review. J Am Osteopath Assoc 2014; 114: 470-479
• 662 Hundscheid HW, Pepels MJ, Engels LG. et al Treatment of irritable bowel syndrome with osteopathy: results of a randomized controlled pilot study. J Gastroenterol Hepatol 2007; 22: 1394-1398
• 663 Hsu HH, Leung WH, Hu GC. Treatment of irritable bowel syndrome with a novel colonic irrigation system: a pilot study. Tech Coloproctol 2016; 20: 551-557
• 664 Fassov J, Brock C, Lundby L. et al Sacral nerve stimulation changes rectal sensitivity and biomechanical properties in patients with irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 1597-1604
• 665 Fassov J, Lundby L, Laurberg S. et al Three-year follow-up of sacral nerve stimulation for patients with diarrhoea-predominant and mixed irritable bowel syndrome. Colorectal Dis 2016; 19: 188-193
• 666 Fassov J, Lundby L, Worsoe J. et al A randomised, controlled study of small intestinal motility in patients treated with sacral nerve stimulation for irritable bowel syndrome. BMC Gastroenterol 2014; 14: 111
• 667 Fassov JL, Lundby L, Laurberg S. et al A randomized, controlled, crossover study of sacral nerve stimulation for irritable bowel syndrome. Ann Surg 2014; 260: 31-36
• 668 Lundby L, Krogh K, Buntzen S. et al Temporary sacral nerve stimulation for treatment of irritable bowel syndrome: a pilot study. Dis Colon Rectum 2008; 51: 1074-1078
• 669 Tipsmark LS, Fassov J, Lundby L. et al Cost-effectiveness analysis of sacral nerve stimulation as treatment for severe irritable bowel syndrome. Colorectal Dis 2016; 18: O30-O36
• 670 Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with Loperamide in irritable bowel syndrome. Scandinavian Journal of Gastroenterology 1996; 31: 463-468
• 671 Lavö B, Stenstam M, Nielsen A. Loperamide in treatment of irritable bowel syndrome – a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987: 77-80
• 672 Cann P, Read N, Holdworth C. et al Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-247
• 673 Camilleri M, Acosta A, Busciglio I. et al Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41: 438-448
• 674 Lembo AJ, Lacy BE, Zuckerman MJ. et al Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med 2016; 374: 242-253
• 675 Dove LS, Lembo A, Randall CW. et al Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013; 145: 329-338.e321
• 676 Fant RV, Henningfield JE, Cash BD. et al Eluxadoline Demonstrates a Lack of Abuse Potenzial in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea. Clin Gastroenterol Hepatol 2017; 15: 1021-1029 e1026
• 677 Lacy BE, Chey WD, Cash BD. et al Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol 2017; 112: 924-932
• 678 Cash BD, Lacy BE, Schoenfeld PS. et al Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol 2017; 112: 365-374
• 679 Chey WD, Dove LS, Andrae DA. et al Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies. Aliment Pharmacol Ther 2017; 45: 1319-1328
• 680 Andresen V, Montori VM, Keller J. et al Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6: 545-555
• 681 Zheng Y, Yu T, Tang Y. et al Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2017; 12: e0172846
• 682 Qi Q, Zhang Y, Chen F. et al Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol 2018; 18: 5
• 683 Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30: 884-901
• 684 Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86
• 685 Ford AC, Brandt LJ, Young C. et al Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-1843 ; quiz 1844
• 686 Garsed K, Chernova J, Hastings M. et al A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014; 63: 1617-1625
• 687 Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936-971
• 688 Minguez M, Lopez Higueras A, Judez J. Use of polyethylene glycol in functional constipation and fecal impaction. Rev Esp Enferm Dig 2016; 108: 790-806
• 689 Chapman RW, Stanghellini V, Geraint M. et al Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108: 1508-1515
• 690 Katelaris P, Naganathan V, Liu K. et al Comparison of the effectiveness of polyethylene glycol with and without electrolytes in constipation: a systematic review and network meta-analysis. BMC Gastroenterol 2016; 16: 42
• 691 Szojda MM, Mulder CJ, Felt-Bersma RJ. Differences in taste between two polyethylene glycol preparations. J Gastrointestin Liver Dis 2007; 16: 379-381
• 692 Belsey JD, Geraint M, Dixon TA. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 2010; 64: 944-955
• 693 Seinela L, Sairanen U, Laine T. et al Comparison of polyethylene glycol with and without electrolytes in the treatment of constipation in elderly institutionalized patients: a randomized, double-blind, parallel-group study. Drugs Aging 2009; 26: 703-713
• 694 Cinca R, Chera D, Gruss HJ. et al Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment. Aliment Pharmacol Ther 2013; 37: 876-886
• 695 Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011; 60: 209-218
• 696 Medoff J, Katz S, Malik P. et al Open-label, dose-ranging pilot study of 4 weeks of low-dose therapy with sodium phosphate tablets in chronically constipated adults. Clin Ther 2004; 26: 1479-1491
• 697 Miller LE, Tennila J, Ouwehand AC. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol 2014; 7: 241-248
• 698 Mueller-Lissner S, Kamm MA, Wald A. et al Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010; 105: 897-903
• 699 Soufi-Afshar I, Moghadamnia A, Bijani A. et al Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation. Caspian J Intern Med 2016; 7: 19-24
• 700 Kamm MA, Mueller-Lissner S, Wald A. et al Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 2011; 9: 577-583
• 701 Sajid MS, Hebbar M, Baig MK. et al Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials. J Neurogastroenterol Motil 2016; 22: 412-422
• 702 Tack J, Stanghellini V, Dubois D. et al Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2014; 26: 21-27
• 703 Mozaffari S, Nikfar S, Abdollahi M. Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients. Arch Med Sci 2014; 10: 10-18
• 704 Shin A, Camilleri M, Kolar G. et al Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014; 39: 239-253
• 705 Yu SW, Rao SS. Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol 2014; 7: 193-205
• 706 Shah ED, Kim HM, Schoenfeld P. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2018; 113: 329-338
• 707 Eutamene H, Bradesi S, Larauche M. et al Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22: 312-e384
• 708 Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014; 147: 1149-1172.e1142
• 709 Atluri DK, Chandar AK, Bharucha AE. et al Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil 2014; 26: 499-509
• 710 Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1084-1092.e1083 ; quiz e1068
• 711 Quigley EM, Tack J, Chey WD. et al Randomised clinical trials: linaclotide phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37: 49-61
• 712 Johnston JM, Kurtz CB, Macdougall JE. et al Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-1886.e1872
• 713 Chey WD, Lembo AJ, Lavins BJ. et al Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-1712
• 714 Rao S, Lembo AJ, Shiff SJ. et al A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-1724 ; quiz p.1725
• 715 Rao SS, Quigley EM, Shiff SJ. et al Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2014; 12: 616-623
• 716 Chey W, Lembo A. et al Efficacy and Safety of Once-daily Linaclotide Administered Orally for 12 Weeks to Patients with IBS-C:. Am J Gastroenterol 2012; 107: 1702
• 717 Miner P, DeLuca R, La Portilla M. et al Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C). Am J Gastroenterol 2014; 109 (Suppl. 02) S541
• 718 Brenner DM, Fogel R, Dorn SD. et al Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018; 113: 735-745
• 719 Wilson N, Schey R. Lubiprostone in constipation: clinical evidence and place in therapy. Ther Adv Chronic Dis 2015; 6: 40-50
• 720 Camilleri M, Bharucha AE, Ueno R. et al Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-G947
• 721 Drossman DA, Chey WD, Johanson JF. et al Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-341
• 722 Li F, Fu T, Tong WD. et al Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clin Proc 2016; 91: 456-468
• 723 Ruepert L, Quartero AO, de Wit NJ. et al Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011:CD003460
• 724 Ford AC, Talley NJ, Spiegel BM. et al Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313
• 725 Clave P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Therap Adv Gastroenterol 2017; 10: 311-322
• 726 Clave P, Acalovschi M, Triantafillidis JK. et al Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 432-442
• 727 Chmielewska-Wilkon D, Reggiardo G, Egan CG. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial. World J Gastroenterol 2014; 20: 12283-12291
• 728 Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. J Clin Med 2017; 6: 101
• 729 Ford AC, Quigley EM, Lacy BE. et al Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1350-1365 ; quiz 1366
• 730 Xie C, Tang Y, Wang Y. et al Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis. PLoS One 2015; 10: e0127815
• 731 Chao GQ, Zhang S. A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Intern Med 2013; 52: 419-424
• 732 Lewis-Fernandez R, Lam P, Lucak S. et al An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. J Clin Psychopharmacol 2016; 36: 710-715
• 733 Kaplan A, Franzen MD, Nickell PV. et al An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract 2014; 18: 11-15
• 734 Brennan BP, Fogarty KV, Roberts JL. et al Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009; 24: 423-428
• 735 Vahedi H, Merat S, Momtahen S. et al Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 678-684
• 736 Vahedi H, Merat S, Rashidioon A. et al The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005; 22: 381-385
• 737 Schafer E, Ewe K. [The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]. Fortschr Med 1990; 108: 488-492
• 738 Mueller-Lissner S, Tytgat GN, Paulo LG. et al Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006; 23: 1741-1748
• 739 Szarka LA, Camilleri M, Burton D. et al Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 1268-1275
• 740 Mangel AW, Bornstein JD, Hamm LR. et al Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 239-249
• 741 Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995; 40: 2244-2249
• 742 Delvaux M, Louvel D, Lagier E. et al The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116: 38-45
• 743 Hawkes ND, Rhodes J, Evans BK. et al Naloxone treatment for irritable bowel syndrome – a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002; 16: 1649-1654
• 744 Kariv R, Tiomny E, Grenshpon R. et al Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Dig Dis Sci 2006; 51: 2128-2133
• 745 Saito YA, Almazar AE, Tilkes KE. et al Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019; 49: 389-397
• 746 Houghton LA, Fell C, Whorwell PJ. et al Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56: 1218-1225
• 747 Simren M. Bloating and abdominal distention: not so poorly understood anymore!. Gastroenterology 2009; 136: 1487-1490
• 748 Accarino A, Perez F, Azpiroz F. et al Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology 2009; 136: 1544-1551
• 749 Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-19
• 750 Wittmann T, Paradowski L, Ducrotte P. et al Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010; 31: 615-624
• 751 Ducrotte P, Grimaud JC, Dapoigny M. et al On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract 2014; 68: 245-254
• 752 Hyams JS, Di Lorenzo C, Saps M. et al Functional Disorders: Children and Adolescents. Gastroenterology 2016; 15: S0016-5085
• 753 Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 19: S0016-5085
• 754 Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil 2017; 23: 151-163
• 755 Baber KF, Anderson J, Puzanovova M. et al Rome II versus Rome III classification of functional gastrointestinal disorders in pediatric chronic abdominal pain. J Pediatr Gastroenterol Nutr 2008; 47: 299-302
• 756 Rutten JM, Benninga MA, Vlieger AM. IBS and FAPS in children: a comparison of psychological and clinical characteristics. J Pediatr Gastroenterol Nutr 2014; 59: 493-499
• 757 Helgeland H, Flagstad G, Grotta J. et al Diagnosing pediatric functional abdominal pain in children (4-15 years old) according to the Rome III Criteria: results from a Norwegian prospective study. J Pediatr Gastroenterol Nutr 2009; 49: 309-315
• 758 Saps M, Velasco-Benitez CA, Langshaw AH. et al Prevalence of Functional Gastrointestinal Disorders in Children and Adolescents: Comparison Between Rome III and Rome IV Criteria. J Pediatr 2018; 199: 212-216
• 759 Saps M, Nichols-Vinueza DX, Mintjens S. et al Construct validity of the pediatric Rome III criteria. J Pediatr Gastroenterol Nutr 2014; 59: 577-581
• 760 Friesen CA, Rosen JM, Schurman JV. Prevalence of overlap syndromes and symptoms in pediatric functional dyspepsia. BMC Gastroenterol 2016; 16: 75
• 761 Gijsbers CF, Benninga MA, Schweizer JJ. et al Validation of the Rome III criteria and alarm symptoms for recurrent abdominal pain in children. J Pediatr Gastroenterol Nutr 2014; 58: 779-785
• 762 Czyzewski DI, Lane MM, Weidler EM. et al The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children. Aliment Pharmacol Ther 2011; 33: 403-411
• 763 Gijsbers CF, Kneepkens CM, Vergouwe Y. et al Occult constipation: faecal retention as a cause of recurrent abdominal pain in children. Eur J Pediatr 2014; 173: 781-785
• 764 Garralda ME. Practitioner review: Assessment and management of somatisation in childhood and adolescence: a practical perspective. J Child Psychol Psychiatry 1999; 40: 1159-1167
• 765 Hausteiner-Wiehle C, Henningsen P. Irritable bowel syndrome: relations with functional, mental, and somatoform disorders. World J Gastroenterol 2014; 20: 6024-6030
• 766 Korterink JJ, Diederen K, Benninga MA. et al Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One 2015; 10: e0126982
• 767 Gulewitsch MD, Enck P, Schwille-Kiuntke J. et al Rome III criteria in parents’ hands: pain-related functional gastrointestinal disorders in community children and associations with somatic complaints and mental health. Eur J Gastroenterol Hepatol 2013; 25: 1223-1229
• 768 Ellert U, Neuhauser H, Roth-Isigkeit A. [Pain in children and adolescents in Germany: the prevalence and usage of medical services. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 711-717
• 769 Hoekman DR, Rutten JM, Vlieger AM. et al Annual Costs of Care for Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome. J Pediatr 2015; 167: 1103-1108 e1102
• 770 Devanarayana NM, de Silva DG, de Silva HJ. Aetiology of recurrent abdominal pain in a cohort of Sri Lankan children. J Paediatr Child Health 2008; 44: 195-200
• 771 Friedrichsdorf SJ, Giordano J, Desai Dakoji K. et al Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain Disorders in Head, Abdomen, Muscles and Joints. Children (Basel) 2016; 3: 42
• 772 Waters AM, Schilpzand E, Bell C. et al Functional gastrointestinal symptoms in children with anxiety disorders. J Abnorm Child Psychol 2013; 41: 151-163
• 773 Gieteling MJ, Bierma-Zeinstra SM, Lisman-van Leeuwen Y. et al Prognostic factors for persistence of chronic abdominal pain in children. J Pediatr Gastroenterol Nutr 2011; 52: 154-161
• 774 Assa A, Ish-Tov A, Rinawi F. et al School Attendance in Children With Functional Abdominal Pain and Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr 2015; 61: 553-557
• 775 Varni JW, Bendo CB, Nurko S. et al Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr 2015; 166: 85-90
• 776 Youssef NN, Murphy TG, Langseder AL. et al Quality of life for children with functional abdominal pain: a comparison study of patients’ and parents’ perceptions. Pediatrics 2006; 117: 54-59
• 777 Bengtson MB, Ronning T, Vatn MH. et al Irritable bowel syndrome in twins: genes and environment. Gut 2006; 55: 1754-1759
• 778 Bengtson MB, Aamodt G, Vatn MH. et al Co-occurrence of IBS and symptoms of anxiety or depression, among Norwegian twins, is influenced by both heredity and intrauterine growth. BMC Gastroenterol 2015; 15: 9
• 779 Henstrom M, D’Amato M. Genetics of irritable bowel syndrome. Mol Cell Pediatr 2016; 3: 7
• 780 Makker J, Chilimuri S, Bella JN. Genetic epidemiology of irritable bowel syndrome. World J Gastroenterol 2015; 21: 11353-11361
• 781 Bonilla S, Saps M. Early life events predispose the onset of childhood functional gastrointestinal disorders. Rev Gastroenterol Mex 2013; 78: 82-91
• 782 Bradford K, Shih W, Videlock EJ. et al Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012; 10: 385-390 e381-e383
• 783 Rosen JM, Kriegermeier A, Adams PN. et al Urinary tract infection in infancy is a risk factor for chronic abdominal pain in childhood. J Pediatr Gastroenterol Nutr 2015; 60: 214-216
• 784 Saps M, Bonilla S. Early life events: infants with pyloric stenosis have a higher risk of developing chronic abdominal pain in childhood. J Pediatr 2011; 159: 551-554 e551
• 785 Saps M, Lu P, Bonilla S. Cow’s-milk allergy is a risk factor for the development of FGIDs in children. J Pediatr Gastroenterol Nutr 2011; 52: 166-169
• 786 Saps M, Dhroove G, Chogle A. Henoch-Schonlein purpura leads to functional gastrointestinal disorders. Dig Dis Sci 2011; 56: 1789-1793
• 787 Saps M, Pensabene L, Turco R. et al Rotavirus gastroenteritis: precursor of functional gastrointestinal disorders?. J Pediatr Gastroenterol Nutr 2009; 49: 580-583
• 788 Keszthelyi D, Troost FJ, Simren M. et al Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain 2012; 16: 1444-1454
• 789 Liu X, Silverman A, Kern M. et al Excessive coupling of the salience network with intrinsic neurocognitive brain networks during rectal distension in adolescents with irritable bowel syndrome: a preliminary report. Neurogastroenterol Motil 2016; 28: 43-53
• 790 Mayer EA, Labus JS, Tillisch K. et al Towards a systems view of IBS. Nat Rev Gastroenterol Hepatol 2015; 12: 592-605
• 791 Williams AE, Heitkemper M, Self MM. et al Endogenous inhibition of somatic pain is impaired in girls with irritable bowel syndrome compared with healthy girls. J Pain 2013; 14: 921-930
• 792 Halac U, Noble A, Faure C. Rectal sensory threshold for pain is a diagnostic marker of irritable bowel syndrome and functional abdominal pain in children. J Pediatr 2010; 156: 60-65.e61
• 793 Saulnier DM, Riehle K, Mistretta TA. et al Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1782-1791
• 794 Rajilic-Stojanovic M, Jonkers DM, Salonen A. et al Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?. Am J Gastroenterol 2015; 110: 278-287
• 795 Chumpitazi BP, Cope JL, Hollister EB. et al Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 2015; 42: 418-427
• 796 Benninga MA, Mayer EA. The power of placebo in pediatric functional gastrointestinal disease. Gastroenterology 2009; 137: 1207-1210
• 797 De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?. Gut 2016; 65: 169-178
• 798 Hoekman DR, Zeevenhooven J, van Etten-Jamaludin FS. et al The Placebo Response in Pediatric Abdominal Pain-Related Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis. J Pediatr 2017; 182: 155-163 e157
• 799 Hoffmann KM, Gruber E, Deutschmann A. et al Histamine intolerance in children with chronic abdominal pain. Arch Dis Child 2013; 98: 832-833
• 800 Thomson S, Dancey CP. Symptoms of irritable bowel in school children: prevalence and psychosocial effects. J Pediatr Health Care 1996; 10: 280-285
• 801 Claar RL, Walker LS, Smith CA. Functional disability in adolescents and young adults with symptoms of irritable bowel syndrome: the role of academic, social, and athletic competence. J Pediatr Psychol 1999; 24: 271-280
• 802 Campo JV, Bridge J, Ehmann M. et al Recurrent abdominal pain, anxiety, and depression in primary care. Pediatrics 2004; 113: 817-824
• 803 Campo JV, Bridge J, Lucas A. et al Physical and emotional health of mothers of youth with functional abdominal pain. Arch Pediatr Adolesc Med 2007; 161: 131-137
• 804 Calvano C, Warschburger P. Chronic Abdominal Pain in Children and Adolescents: Parental Threat Perception Plays a Major Role in Seeking Medical Consultations. Pain Res Manag 2016; 2016: 3183562
• 805 Crushell E, Rowland M, Doherty M. et al Importance of parental conceptual model of illness in severe recurrent abdominal pain. Pediatrics 2003; 112: 1368-1372
• 806 Di Lorenzo C, Colletti RB, Lehmann HP. et al Chronic abdominal pain in children: a clinical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40: 245-248
• 807 Gijsbers CF, Benninga M, Buller H. Clinical and laboratory findings in 220 children with recurrent abdominal pain. Acta Paediatr 2011; 100: 1028-1032
• 808 Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 637-645
• 809 Gijsbers CF, Schweizer JJ, Buller HA. Protozoa as a cause of recurrent abdominal pain in children. J Pediatr Gastroenterol Nutr 2013; 57: 603-606
• 810 Holtman GA, Kranenberg JJ, Blanker MH. et al Dientamoeba fragilis colonization is not associated with gastrointestinal symptoms in children at primary care level. Fam Pract 2017; 34: 25-29
• 811 Yip WC, Ho TF, Yip YY. et al Value of abdominal sonography in the assessment of children with abdominal pain. J Clin Ultrasound 1998; 26: 397-400
• 812 Gijsbers CF, Kneepkens CM, Buller HA. Lactose and fructose malabsorption in children with recurrent abdominal pain: results of double-blinded testing. Acta Paediatr 2012; 101: e411-415
• 813 Wirth S, Klodt C, Wintermeyer P. et al Positive or negative fructose breath test results do not predict response to fructose restricted diet in children with recurrent abdominal pain: results from a prospective randomized trial. Klin Padiatr 2014; 226: 268-273
• 814 Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2011; 52: 382-386
• 815 Korterink JJ, Benninga MA, van Wering HM. et al Glucose hydrogen breath test for small intestinal bacterial overgrowth in children with abdominal pain-related functional gastrointestinal disorders. J Pediatr Gastroenterol Nutr 2015; 60: 498-502
• 816 Scarpellini E, Giorgio V, Gabrielli M. et al Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr 2009; 155: 416-420
• 817 Shelby GD, Shirkey KC, Sherman AL. et al Functional abdominal pain in childhood and long-term vulnerability to anxiety disorders. Pediatrics 2013; 132: 475-482
• 818 Zhou H, Li D, Cheng G. et al An epidemiologic study of irritable bowel syndrome in adolescents and children in South China: a school-based study. Child Care Health Dev 2010; 36: 781-786
• 819 Yacob D, Di Lorenzo C, Bridge JA. et al Prevalence of pain-predominant functional gastrointestinal disorders and somatic symptoms in patients with anxiety or depressive disorders. J Pediatr 2013; 163: 767-770
• 820 Cunningham NR, Cohen MB, Farrell MK. et al Concordant parent-child reports of anxiety predict impairment in youth with functional abdominal pain. J Pediatr Gastroenterol Nutr 2015; 60: 312-317
• 821 Reed-Knight B, Claar RL, Schurman JV. et al Implementing psychological therapies for functional GI disorders in children and adults. Expert Rev Gastroenterol Hepatol 2016; 10: 981-984
• 822 Walker LS, Williams SE, Smith CA. et al Parent attention versus distraction: impact on symptom complaints by children with and without chronic functional abdominal pain. Pain 2006; 122: 43-52
• 823 Korterink JJ, Rutten JM, Venmans L. et al Pharmacologic treatment in pediatric functional abdominal pain disorders: a systematic review. J Pediatr 2015; 166: 424-431.e426
• 824 Martin AE, Newlove-Delgado TV, Abbott RA. et al Pharmacological interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017; 3: CD010973
• 825 Kline RM, Kline JJ, Di Palma J. et al Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001; 138: 125-128
• 826 Madani S, Cortes O, Thomas R. Cyproheptadine Use in Children With Functional Gastrointestinal Disorders. J Pediatr Gastroenterol Nutr 2016; 62: 409-413
• 827 Bahar RJ, Collins BS, Steinmetz B. et al Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008; 152: 685-689
• 828 Saps M, Youssef N, Miranda A. et al Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009; 137: 1261-1269
• 829 Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 191-196
• 830 Koppen IJN, Broekaert IJ, Wilschanski M. et al Role of Polyethylene Glycol in the Treatment of Functional Constipation in Children. J Pediatr Gastroenterol Nutr 2017; 65: 361-363
• 831 Lee-Robichaud H, Thomas K, Morgan J. et al Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database Syst Rev 2010:Cd007570
• 832 Tabbers MM, DiLorenzo C, Berger MY. et al Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58: 258-274
• 833 Newlove-Delgado TV, Martin AE, Abbott RA. et al Dietary interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017; 3: CD010972
• 834 van Tilburg MA, Felix CT. Diet and functional abdominal pain in children and adolescents. J Pediatr Gastroenterol Nutr 2013; 57: 141-148
• 835 Giannetti E, Staiano A. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. J Pediatr Gastroenterol Nutr 2016; 63 (Suppl. 01) S25-S26
• 836 Guandalini S. Are probiotics or prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease?. Front Med (Lausanne) 2014; 1: 23
• 837 Parker EA, Roy T, D’Adamo CR. et al Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45: 125-134 e111
• 838 Abbott RA, Martin AE, Newlove-Delgado TV. et al Psychosocial interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev 2017; 1: CD010971
• 839 Eccleston C, Palermo TM, Williams AC. et al Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev 2014:Cd003968
• 840 Rutten JM, Korterink JJ, Venmans LM. et al Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review. Pediatrics 2015; 135: 522-535
• 841 Levy RL, Langer SL, Walker LS. et al Cognitive-behavioral therapy for children with functional abdominal pain and their parents decreases pain and other symptoms. Am J Gastroenterol 2010; 105: 946-956
• 842 Levy RL, Langer SL, Walker LS. et al Twelve-month follow-up of cognitive behavioral therapy for children with functional abdominal pain. JAMA Pediatr 2013; 167: 178-184
• 843 Levy RL, Langer SL, van Tilburg MA. et al Brief telephone-delivered cognitive behavioral therapy targeted to parents of children with functional abdominal pain: a randomized controlled trial. Pain 2017; 158: 618-628
• 844 Duarte MA, Penna FJ, Andrade EM. et al Treatment of nonorganic recurrent abdominal pain: cognitive-behavioral family intervention. J Pediatr Gastroenterol Nutr 2006; 43: 59-64
• 845 Robins PM, Smith SM, Glutting JJ. et al A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain. J Pediatr Psychol 2005; 30: 397-408
• 846 Gross M, Warschburger P. Evaluation of a cognitive-behavioral pain management program for children with chronic abdominal pain: a randomized controlled study. Int J Behav Med 2013; 20: 434-443
• 847 Sanders MR, Rebgetz M, Morrison M. et al Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects. J Consult Clin Psychol 1989; 57: 294-300
• 848 Sanders MR, Shepherd RW, Cleghorn G. et al The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care. J Consult Clin Psychol 1994; 62: 306-314
• 849 van der Veek SM, Derkx BH, Benninga MA. et al Cognitive behavior therapy for pediatric functional abdominal pain: a randomized controlled trial. Pediatrics 2013; 132: e1163-1172
• 850 Warschburger P, Calvano C, Becker S. et al Stop the pain: study protocol for a randomized-controlled trial. Trials 2014; 15: 357
• 851 Gulewitsch MD, Muller J, Hautzinger M. et al Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and irritable bowel syndrome in childhood: a randomized controlled trial. Eur J Pediatr 2013; 172: 1043-1051
• 852 van Tilburg MA, Chitkara DK, Palsson OS. et al Audio-recorded guided imagery treatment reduces functional abdominal pain in children: a pilot study. Pediatrics 2009; 124: e890-897
• 853 Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC. et al Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007; 133: 1430-1436
• 854 Weydert JA, Shapiro DE, Acra SA. et al Evaluation of guided imagery as treatment for recurrent abdominal pain in children: a randomized controlled trial. BMC Pediatr 2006; 6: 29
• 855 Vlieger AM, Rutten JM, Govers AM. et al Long-term follow-up of gut-directed hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome. Am J Gastroenterol 2012; 107: 627-631
• 856 Rutten JM, Vlieger AM, Frankenhuis C. et al Gut-directed hypnotherapy in children with irritable bowel syndrome or functional abdominal pain (syndrome): a randomized controlled trial on self exercises at home using CD versus individual therapy by qualified therapists. BMC Pediatr 2014; 14: 140
• 857 Rutten J, Vlieger AM, Frankenhuis C. et al Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial. JAMA Pediatr 2017; 171: 470-477
• 858 Korterink JJ, Ockeloen LE, Hilbink M. et al Yoga Therapy for Abdominal Pain-Related Functional Gastrointestinal Disorders in Children: A Randomized Controlled Trial. J Pediatr Gastroenterol Nutr 2016; 63: 481-487
• 859 Kuttner L, Chambers CT, Hardial J. et al A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag 2006; 11: 217-223
• 860 Wallander JL, Madan-Swain A, Klapow J. et al A randomised controlled trial of written self-disclosure for functional recurrent abdominal pain in youth. Psychol Health 2011; 26: 433-447
• 861 Vlieger AM, Blink M, Tromp E. et al Use of complementary and alternative medicine by pediatric patients with functional and organic gastrointestinal diseases: results from a multicenter survey. Pediatrics 2008; 122: e446-451
• 862 Lobo B, Ramos L, Martinez C. et al Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterol J 2017; 5: 887-897
• 863 Banasiewicz T, Krokowicz L, Stojcev Z. et al Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013; 15: 204-209
• 864 Di Nardo G, Oliva S, Ferrari F. et al Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. BMC Gastroenterol 2013; 13: 142
• 865 Leffler DA, Kelly CP, Green PH. et al Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 2015; 148: 1311-1319 e1316
• 866 Odunsi-Shiyanbade ST, Camilleri M, McKinzie S. et al Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-165
• 867 Chey WD, Camilleri M, Chang L. et al A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011; 106: 1803-1812
• 868 Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol 2014; 7: 167-175
• 869 Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013; 22: 277-284
• 870 Spencer AG, Jacobs JW, Leadbetter MR. et al RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology 2011; 140: s-99
• 871 Spencer AG, Labonte ED, Rosenbaum DP. et al Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med 2014; 6: 227ra236
• 872 Eutamene H, Charmot D, Navre M. et al Visceral Antinociceptive Effects of RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor on StressInduced Colorectal Hypersensitivity to Distension in Rats. Gastroenterology 2011; 140: S57-S58
• 873 Rosenbaum DP, Spencer AG, Jacobs JW. et al The Safety, Tolerability, Systemic Exposure, and Effect on Bowel Habits of Single and Multiple Doses of the Intestinal Sodium Re-Uptake Inhibitor RDX5791 in Normal Healthy Volunteers. Am J Gastroenterol 2011; 106: S504
• 874 Song GH, Leng PH, Gwee KA. et al Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-1407
• 875 Lu WZ, Song GH, Gwee KA. et al The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009; 54: 1087-1093
• 876 Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil 2011; 23: 193-200
• 877 Lembo A, Huber J, Schinagl RM. et al Efficacy and Safety of ASP7147, a Bombesin-2 Receptor Antagonist, in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): Results of a Multicenter, Double-Blind, Placebo-Controlled Trial. Gastroenterology 2015; 148: S69
• 878 Hellstrom PM, Hein J, Bytzer P. et al Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009; 29: 198-206
• 879 Mosinska P, Storr M, Fichna J. The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. Therap Adv Gastroenterol 2015; 8: 278-284
• 880 Tack JF, Miner Jr PB, Fischer L. et al Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome – a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 868-877
• 881 Corsetti M, Akyuz F, Tack J. Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome. Neurogastroenterol Motil 2015; 27: 1354-1370
• 882 Lee KN, Lee OY, Choi MG. et al Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium. J Neurogastroenterol Motil 2014; 20: 113-121